Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in Breast Cancer Res Treat

Retrieve available abstracts of 613 articles:
HTML format



Single Articles


    January 2022
  1. CONDORELLI M, Sens M, Goldrat O, Delbaere A, et al
    A retrospective study evaluating the impact of scattering radiation from imaging procedures on oocyte quality during ovarian stimulation for fertility preservation in young breast cancer patients.
    Breast Cancer Res Treat. 2022 Jan 18. pii: 10.1007/s10549-021-06489.
    PubMed     Abstract available


  2. MARTINEZ JA, Wertheim BC, Roe DJ, Chalasani P, et al
    Sulindac Improves Stiffness and Quality of Life in Women Taking Aromatase Inhibitors for Breast Cancer.
    Breast Cancer Res Treat. 2022 Jan 18. pii: 10.1007/s10549-021-06485.
    PubMed     Abstract available


  3. SUELMANN BBM, Bakhuis CFJ, van Dooijeweert C, Verloop J, et al
    Prognosis of pregnancy-associated breast cancer: inferior outcome in patients diagnosed during second and third gestational trimesters and lactation.
    Breast Cancer Res Treat. 2022 Jan 18. pii: 10.1007/s10549-021-06471.
    PubMed     Abstract available


  4. LIANG Y, Besch-Williford C, Hyder SM
    The estrogen receptor beta agonist liquiritigenin enhances the inhibitory effects of the cholesterol biosynthesis inhibitor RO 48-8071 on hormone-dependent breast-cancer growth.
    Breast Cancer Res Treat. 2022 Jan 17. pii: 10.1007/s10549-021-06487.
    PubMed     Abstract available


  5. JONES GS, Hoadley KA, Benefield H, Olsson LT, et al
    Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression.
    Breast Cancer Res Treat. 2022 Jan 16. pii: 10.1007/s10549-021-06497.
    PubMed     Abstract available


  6. PAVANELLI AC, Mangone FR, Yoganathan P, Bessa SA, et al
    Comprehensive immunohistochemical analysis of RET, BCAR1, and BCAR3 expression in patients with Luminal A and B breast cancer subtypes.
    Breast Cancer Res Treat. 2022 Jan 15. pii: 10.1007/s10549-021-06452.
    PubMed     Abstract available


  7. CHOI SB, Park JM, Ahn JH, Go J, et al
    Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?
    Breast Cancer Res Treat. 2022 Jan 13. pii: 10.1007/s10549-022-06519.
    PubMed     Abstract available


  8. ALTERIO D, La Rocca E, Volpe S, Camarda AM, et al
    Hypofractionated proton therapy in breast cancer: where are we? A critical review of the literature.
    Breast Cancer Res Treat. 2022 Jan 13. pii: 10.1007/s10549-022-06516.
    PubMed     Abstract available


  9. MEEGDES M, Ibragimova KIE, Lobbezoo DJA, Vriens IJH, et al
    The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry.
    Breast Cancer Res Treat. 2022 Jan 13. pii: 10.1007/s10549-021-06472.
    PubMed     Abstract available


  10. FASANO GA, Bayard S, Chen Y, Varella L, et al
    Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer.
    Breast Cancer Res Treat. 2022 Jan 13. pii: 10.1007/s10549-021-06481.
    PubMed     Abstract available


  11. ANGARITA FA, Oshi M, Yamada A, Yan L, et al
    Low RUFY3 expression level is associated with lymph node metastasis in older women with invasive breast cancer.
    Breast Cancer Res Treat. 2022 Jan 12. pii: 10.1007/s10549-021-06482.
    PubMed     Abstract available


  12. YOO TK, Kang J, Lee A, Chae BJ, et al
    A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes.
    Breast Cancer Res Treat. 2022 Jan 12. pii: 10.1007/s10549-021-06437.
    PubMed     Abstract available


  13. VERDONE CG, Bayron JA, Chang C, Wang CE, et al
    A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA.
    Breast Cancer Res Treat. 2022 Jan 11. pii: 10.1007/s10549-021-06460.
    PubMed     Abstract available


  14. PATEL R, Li Z, Zimmerman BS, Fink MY, et al
    Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2022 Jan 10. pii: 10.1007/s10549-021-06504.
    PubMed     Abstract available


  15. DONZELLA SM, Lind KE, Skiba MB, Farland LV, et al
    The relationship between sleep and weight change among women diagnosed with breast cancer participating in the Women's Health Initiative.
    Breast Cancer Res Treat. 2022 Jan 10. pii: 10.1007/s10549-021-06486.
    PubMed     Abstract available


  16. VOHRA SN, Reeder-Hayes KE, Nichols HB, Emerson MA, et al
    Breast cancer treatment patterns by age and time since last pregnancy in the Carolina Breast Cancer Study Phase III.
    Breast Cancer Res Treat. 2022 Jan 10. pii: 10.1007/s10549-022-06511.
    PubMed     Abstract available


  17. SARMA M, Perimbeti S, Nasir S, Attwood K, et al
    Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study.
    Breast Cancer Res Treat. 2022 Jan 9. pii: 10.1007/s10549-021-06506.
    PubMed     Abstract available


  18. CHEUNG YM, Cromwell GE, Tolaney SM, Min L, et al
    Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer.
    Breast Cancer Res Treat. 2022 Jan 9. pii: 10.1007/s10549-021-06476.
    PubMed     Abstract available


  19. LEE J, Chang Y, Kim Y, Park B, et al
    Insulin resistance and the development of breast cancer in premenopausal women: the Kangbuk Samsung Health Study.
    Breast Cancer Res Treat. 2022 Jan 8. pii: 10.1007/s10549-022-06513.
    PubMed     Abstract available


  20. ANDERSON RA, Kelsey TW, Perdrix A, Olympios N, et al
    Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer.
    Breast Cancer Res Treat. 2022 Jan 8. pii: 10.1007/s10549-021-06508.
    PubMed     Abstract available


  21. CONLEY CC, McIntyre M, Pensak NA, Lynce F, et al
    Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study.
    Breast Cancer Res Treat. 2022 Jan 7. pii: 10.1007/s10549-022-06518.
    PubMed     Abstract available


  22. SAGHATCHIAN M, Abehsera M, Yamgnane A, Geyl C, et al
    Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic.
    Breast Cancer Res Treat. 2022 Jan 7. pii: 10.1007/s10549-021-06445.
    PubMed     Abstract available


  23. KIRAC UTKU I, Safer U
    Comment on: sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer-results from the ABLE feasibility trial.
    Breast Cancer Res Treat. 2022 Jan 7. pii: 10.1007/s10549-021-06502.
    PubMed    


  24. BLUMING AZ
    Safety of systemic hormone replacement therapy in breast cancer survivors.
    Breast Cancer Res Treat. 2022 Jan 7. pii: 10.1007/s10549-021-06479.
    PubMed    


  25. ZHENG C, Chagpar AB
    Contribution of cost to treatment nonadherence in the US breast cancer survivors: a population-based analysis.
    Breast Cancer Res Treat. 2022 Jan 6. pii: 10.1007/s10549-022-06510.
    PubMed     Abstract available


  26. TANG A, Neeman E, Vuong B, Arasu VA, et al
    Care in the time of COVID-19: impact on the diagnosis and treatment of breast cancer in a large, integrated health care system.
    Breast Cancer Res Treat. 2022 Jan 6. pii: 10.1007/s10549-021-06468.
    PubMed     Abstract available


  27. BRINGUIER M, Carton M, Levy C, Patsouris A, et al
    Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort.
    Breast Cancer Res Treat. 2022 Jan 5. pii: 10.1007/s10549-021-06467.
    PubMed     Abstract available


  28. COOLBRANDT A, Vancoille K, Dejaeger E, Peeters H, et al
    Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer.
    Breast Cancer Res Treat. 2022 Jan 4. pii: 10.1007/s10549-021-06477.
    PubMed     Abstract available


  29. FALLOWFIELD LJ, Farewell D, Jones H, May S, et al
    IMPARTER, Phase 1 of an intervention to improve patients' understanding of gene expression profiling tests in breast cancer.
    Breast Cancer Res Treat. 2022 Jan 4. pii: 10.1007/s10549-021-06491.
    PubMed     Abstract available


  30. FAN Y, Xie G, Wang Z, Wang Y, et al
    PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy.
    Breast Cancer Res Treat. 2022 Jan 3. pii: 10.1007/s10549-021-06463.
    PubMed     Abstract available


  31. JAGSI R, Mason G, Overmoyer BA, Woodward WA, et al
    Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.
    Breast Cancer Res Treat. 2022 Jan 1. pii: 10.1007/s10549-021-06434.
    PubMed     Abstract available


  32. HU Y, Burkard ME
    Classes of therapeutics to amplify the immune response.
    Breast Cancer Res Treat. 2022;191:277-289.
    PubMed     Abstract available


  33. PAWLOSKI KR, Gonen M, Wen HY, Tadros AB, et al
    Supervised machine learning model to predict oncotype DX risk category in patients over age 50.
    Breast Cancer Res Treat. 2022;191:423-430.
    PubMed     Abstract available


  34. KHAYEKA-WANDABWA C, Zhao J, Pathak JL, Wu H, et al
    Upregulation of estrogen receptor alpha (ERalpha) expression in transgenic mice expressing human CYP4Z1.
    Breast Cancer Res Treat. 2022;191:319-326.
    PubMed     Abstract available


  35. LEWIS PHILLIPS G, Guo J, Kiefer JR, Proctor W, et al
    Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics.
    Breast Cancer Res Treat. 2022;191:303-317.
    PubMed     Abstract available


  36. HUANG L, Wang R, Xie K, Zhang J, et al
    A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation.
    Breast Cancer Res Treat. 2022;191:51-61.
    PubMed     Abstract available


  37. BAKER JL, Haji F, Kusske AM, Fischer CP, et al
    SAVI SCOUT(R) localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study.
    Breast Cancer Res Treat. 2022;191:107-114.
    PubMed     Abstract available


  38. SIEGEL A, Bremer RC, Klein WMP, Savage SA, et al
    Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li-Fraumeni syndrome.
    Breast Cancer Res Treat. 2022;191:159-167.
    PubMed     Abstract available


  39. POULSEN L, Kaur M, Jacobsen AL, Bjarnesen MP, et al
    Comparison of upper extremity lymphedema after sentinel lymph node biopsy and axillary lymph node dissection: patient-reported outcomes in 3044 patients.
    Breast Cancer Res Treat. 2022;191:87-96.
    PubMed     Abstract available


  40. SHIINO S, Ball G, Syed BM, Kurozumi S, et al
    Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis.
    Breast Cancer Res Treat. 2022;191:1-14.
    PubMed     Abstract available


  41. DOLEN UC, Law J, Tenenbaum MM, Myckatyn TM, et al
    Breast reconstruction is a viable option for older patients.
    Breast Cancer Res Treat. 2022;191:77-86.
    PubMed     Abstract available


    December 2021
  42. MORASSO C, Ricciardi A, Sproviero D, Truffi M, et al
    Fast quantification of extracellular vesicles levels in early breast cancer patients by Single Molecule Detection Array (SiMoA).
    Breast Cancer Res Treat. 2021 Dec 21. pii: 10.1007/s10549-021-06474.
    PubMed     Abstract available


  43. YADAV K, Lim J, Choo J, Ow SGW, et al
    Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer.
    Breast Cancer Res Treat. 2021 Dec 20. pii: 10.1007/s10549-021-06470.
    PubMed     Abstract available


  44. SCHAEFGEN B, Funk A, Sinn HP, Bruckner T, et al
    Does conventional specimen radiography after neoadjuvant chemotherapy of breast cancer help to reduce the rate of second surgeries?
    Breast Cancer Res Treat. 2021 Dec 8. pii: 10.1007/s10549-021-06466.
    PubMed     Abstract available


  45. TURNER N, Dent RA, O'Shaughnessy J, Kim SB, et al
    Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
    Breast Cancer Res Treat. 2021 Dec 3. pii: 10.1007/s10549-021-06450.
    PubMed     Abstract available


  46. JAZIEH K, Baidoun F, Torrejon N, Merjaneh Z, et al
    Studying the association between breast cancer and renal cell carcinoma.
    Breast Cancer Res Treat. 2021 Dec 2. pii: 10.1007/s10549-021-06465.
    PubMed     Abstract available


  47. MORGAT C, Brouste V, Chastel A, Velasco V, et al
    Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors.
    Breast Cancer Res Treat. 2021;190:403-413.
    PubMed     Abstract available


  48. NEIRICH L, Yahiaoui-Doktor M, Lammert J, Basrai M, et al
    Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1.
    Breast Cancer Res Treat. 2021;190:463-475.
    PubMed     Abstract available


  49. MINK VAN DER MOLEN DR, Bargon CA, Batenburg MCT, van Stam LE, et al
    The impact of the COVID-19 pandemic on perceived access to health care and preferences for health care provision in individuals (being) treated for breast cancer.
    Breast Cancer Res Treat. 2021 Dec 1. pii: 10.1007/s10549-021-06458.
    PubMed     Abstract available


  50. DINH P, Graham JD, Elder EN, Kabir M, et al
    Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing.
    Breast Cancer Res Treat. 2021 Dec 1. pii: 10.1007/s10549-021-06456.
    PubMed     Abstract available


    November 2021
  51. METCALFE KA, Eisen A, Wright F, Poll A, et al
    Impact of rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis on psychosocial functioning.
    Breast Cancer Res Treat. 2021 Nov 30. pii: 10.1007/s10549-021-06457.
    PubMed     Abstract available


  52. DISIS ML, Cecil DL
    Breast cancer vaccines for treatment and prevention.
    Breast Cancer Res Treat. 2021 Nov 30. pii: 10.1007/s10549-021-06459.
    PubMed     Abstract available


  53. COE F, Misra V, McCabe Y, Adderley H, et al
    Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Nov 29. pii: 10.1007/s10549-021-06438.
    PubMed     Abstract available


  54. DREHER N, Matthys M, Hadeler E, Shieh Y, et al
    A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer.
    Breast Cancer Res Treat. 2021 Nov 29. pii: 10.1007/s10549-021-06451.
    PubMed     Abstract available


  55. BRANDS-APPELDOORN ATPM, Thomma RCM, Janssen L, Maaskant-Braat AJG, et al
    Factors related to patient-reported cosmetic outcome after breast-conserving therapy for breast cancer.
    Breast Cancer Res Treat. 2021 Nov 29. pii: 10.1007/s10549-021-06461.
    PubMed     Abstract available


  56. LI Y, Zheng X, Tu D, Ingle JN, et al
    Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R.
    Breast Cancer Res Treat. 2021 Nov 26. pii: 10.1007/s10549-021-06448.
    PubMed     Abstract available


  57. HARBORG S, Ahern TP, Feldt M, Rosendahl AH, et al
    Circulating lipids and breast cancer prognosis in the Malmo diet and cancer study.
    Breast Cancer Res Treat. 2021 Nov 25. pii: 10.1007/s10549-021-06462.
    PubMed     Abstract available


  58. SMALL BJ, Lange M, Zhai W, Ahn J, et al
    Impact of taxane-based chemotherapy among older women with breast cancer on cognition and quality of life: a longitudinal pooled analysis.
    Breast Cancer Res Treat. 2021 Nov 24. pii: 10.1007/s10549-021-06455.
    PubMed     Abstract available


  59. HONKANEN TJ, Luukkainen MEK, Tikkanen A, Karihtala P, et al
    Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis.
    Breast Cancer Res Treat. 2021 Nov 24. pii: 10.1007/s10549-021-06447.
    PubMed     Abstract available


  60. BARNI S, Cognetti F, Petrelli F
    Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study.
    Breast Cancer Res Treat. 2021 Nov 24. pii: 10.1007/s10549-021-06464.
    PubMed     Abstract available


  61. ROTHSCHILD HT, Abel MK, Patterson A, Goodman K, et al
    Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer.
    Breast Cancer Res Treat. 2021 Nov 24. pii: 10.1007/s10549-021-06453.
    PubMed     Abstract available


  62. SILVER J, Goldenberg A, Moore A
    Dietary supplement use and documentation in a breast cancer survivorship clinic.
    Breast Cancer Res Treat. 2021 Nov 24. pii: 10.1007/s10549-021-06454.
    PubMed     Abstract available


  63. ZUO K, Yuan X, Liang X, Sun X, et al
    qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.
    Breast Cancer Res Treat. 2021 Nov 19. pii: 10.1007/s10549-021-06442.
    PubMed     Abstract available


  64. ROSIER L, Wang Y, Lee JH, Daily K, et al
    Does definitive local therapy have a role in select HER2+ de novo metastatic breast cancer patients treated with dual anti-HER2 blockade?
    Breast Cancer Res Treat. 2021 Nov 17. pii: 10.1007/s10549-021-06440.
    PubMed     Abstract available


  65. JANK P, Lindner JL, Lehmann A, Pfitzner BM, et al
    Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict).
    Breast Cancer Res Treat. 2021 Nov 16. pii: 10.1007/s10549-021-06415.
    PubMed     Abstract available


  66. WU ZY, Han J, Kim HJ, Lee JW, et al
    Breast cancer outcomes following immediate breast reconstruction with implants versus autologous flaps: a propensity score-matched study.
    Breast Cancer Res Treat. 2021 Nov 10. pii: 10.1007/s10549-021-06350.
    PubMed     Abstract available


  67. BOSE M, Benada J, Thatte JV, Kinalis S, et al
    A catalog of curated breast cancer genes.
    Breast Cancer Res Treat. 2021 Nov 10. pii: 10.1007/s10549-021-06441.
    PubMed     Abstract available


  68. KLINGER M, Losurdo A, Lisa AVE, Morenghi E, et al
    Safety of autologous fat grafting in breast cancer: a multicenter Italian study among 17 senonetwork breast units autologous fat grafting safety: a multicenter Italian retrospective study.
    Breast Cancer Res Treat. 2021 Nov 9. pii: 10.1007/s10549-021-06444.
    PubMed     Abstract available


  69. REN M, Orozco A, Shao K, Albanez A, et al
    Correction to: Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer.
    Breast Cancer Res Treat. 2021 Nov 9. pii: 10.1007/s10549-021-06373.
    PubMed    


  70. NYROP KA, Damone EM, Deal AM, Wheeler SB, et al
    Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2021 Nov 5. pii: 10.1007/s10549-021-06439.
    PubMed     Abstract available


  71. POGGIO F, Del Mastro L, Bruzzone M, Ceppi M, et al
    Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2021 Nov 3. pii: 10.1007/s10549-021-06436.
    PubMed     Abstract available


  72. WILSON BE, Gorrini C, Cescon DW
    Breast cancer immune microenvironment: from pre-clinical models to clinical therapies.
    Breast Cancer Res Treat. 2021 Nov 3. pii: 10.1007/s10549-021-06431.
    PubMed     Abstract available


  73. CHO Y, Chang Y, Jung HS, Kim CW, et al
    Fatty liver disease and changes in dense breasts in pre- and postmenopausal women: the Kangbuk Samsung Health Study.
    Breast Cancer Res Treat. 2021;190:343-353.
    PubMed     Abstract available


  74. AMITAI Y, Menes TS, Scaranelo A, Fleming R, et al
    The characteristics associated with upgrade on surgical pathology of conventional imaging occult DCIS diagnosed by MRI.
    Breast Cancer Res Treat. 2021;190:317-327.
    PubMed     Abstract available


  75. ARNONE AA, Cline JM, Soto-Pantoja DR, Cook KL, et al
    Investigating the role of endogenous estrogens, hormone replacement therapy, and blockade of estrogen receptor-alpha activity on breast metabolic signaling.
    Breast Cancer Res Treat. 2021;190:53-67.
    PubMed     Abstract available


  76. AL-KAWAZ A, Ali R, Toss MS, Miligy IM, et al
    The frequency and clinical significance of DNA polymerase beta (POLbeta) expression in breast ductal carcinoma in situ (DCIS).
    Breast Cancer Res Treat. 2021;190:39-51.
    PubMed     Abstract available


  77. TAPIA E, Villa-Guillen DE, Chalasani P, Centuori S, et al
    A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density.
    Breast Cancer Res Treat. 2021;190:69-78.
    PubMed     Abstract available


    October 2021
  78. WU ZY, Kim HJ, Lee J, Chung IY, et al
    Oncologic outcomes of immediate breast reconstruction in young women with breast cancer receiving neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2021 Oct 31. pii: 10.1007/s10549-021-06428.
    PubMed     Abstract available


  79. WAN C, Caston NE, Ingram SA, Rocque GB, et al
    Exclusion criteria of breast cancer clinical trial protocols: a descriptive analysis.
    Breast Cancer Res Treat. 2021 Oct 31. pii: 10.1007/s10549-021-06422.
    PubMed     Abstract available


  80. TORRES ETR, Emens LA
    Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies.
    Breast Cancer Res Treat. 2021 Oct 30. pii: 10.1007/s10549-021-06423.
    PubMed     Abstract available


  81. HUPPERT LA, Mariotti V, Chien AJ, Soliman HH, et al
    Emerging immunotherapeutic strategies for the treatment of breast cancer.
    Breast Cancer Res Treat. 2021 Oct 30. pii: 10.1007/s10549-021-06406.
    PubMed     Abstract available


  82. HO AY, Tabrizi S, Dunn SA, McArthur HL, et al
    Current advances in immune checkpoint inhibitor combinations with radiation therapy or cryotherapy for breast cancer.
    Breast Cancer Res Treat. 2021 Oct 29. pii: 10.1007/s10549-021-06408.
    PubMed     Abstract available


  83. JENKINS JA, Marmor S, Hui JYC, Beckwith H, et al
    The 70-gene signature test as a prognostic and predictive biomarker in patients with invasive lobular breast cancer.
    Breast Cancer Res Treat. 2021 Oct 29. pii: 10.1007/s10549-021-06429.
    PubMed     Abstract available


  84. SCHREIBER AR, Kagihara J, Eguchi M, Kabos P, et al
    Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study.
    Breast Cancer Res Treat. 2021 Oct 27. pii: 10.1007/s10549-021-06424.
    PubMed     Abstract available


  85. LUCANUS AJ, Thike AA, Tan XF, Lee KW, et al
    KIF21A regulates breast cancer aggressiveness and is prognostic of patient survival and tumor recurrence.
    Breast Cancer Res Treat. 2021 Oct 26. pii: 10.1007/s10549-021-06426.
    PubMed     Abstract available


  86. GOLD EB, Crawford SL, Leung K, Greendale G, et al
    Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN.
    Breast Cancer Res Treat. 2021 Oct 25. pii: 10.1007/s10549-021-06425.
    PubMed     Abstract available


  87. CRESCENZI R, Donahue PMC, Garza M, Lee CA, et al
    Elevated magnetic resonance imaging measures of adipose tissue deposition in women with breast cancer treatment-related lymphedema.
    Breast Cancer Res Treat. 2021 Oct 23. pii: 10.1007/s10549-021-06419.
    PubMed     Abstract available


  88. CORBAUX P, Lardy-Cleaud A, Alexandre M, Fontanilles M, et al
    Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Oct 23. pii: 10.1007/s10549-021-06382.
    PubMed     Abstract available


  89. ONEGA T, Zhu W, Kerlikowske K, Miglioretti DL, et al
    Preoperative MRI in breast cancer: effect of breast density on biopsy rate and yield.
    Breast Cancer Res Treat. 2021 Oct 22. pii: 10.1007/s10549-021-06418.
    PubMed     Abstract available


  90. CHIC N, Braso-Maristany F, Prat A
    Biomarkers of immunotherapy response in breast cancer beyond PD-L1.
    Breast Cancer Res Treat. 2021 Oct 21. pii: 10.1007/s10549-021-06421.
    PubMed     Abstract available


  91. MILLS MN, Potluri TK, Kawahara Y, Fahey M, et al
    The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs.
    Breast Cancer Res Treat. 2021 Oct 20. pii: 10.1007/s10549-021-06420.
    PubMed     Abstract available


  92. CAO L, Shenk R, Stabellini N, Miller ME, et al
    Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer: a National Cancer Database analysis.
    Breast Cancer Res Treat. 2021 Oct 16. pii: 10.1007/s10549-021-06411.
    PubMed     Abstract available


  93. LORONA NC, Malone KE, Li CI
    Racial/ethnic disparities in risk of breast cancer mortality by molecular subtype and stage at diagnosis.
    Breast Cancer Res Treat. 2021 Oct 15. pii: 10.1007/s10549-021-06311.
    PubMed     Abstract available


  94. ZHENG F, Du F, Wang W, Wang Y, et al
    Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.
    Breast Cancer Res Treat. 2021 Oct 14. pii: 10.1007/s10549-021-06401.
    PubMed     Abstract available


  95. CHAMSEDDINE RS, Wang C, Yin K, Wang J, et al
    Penetrance of male breast cancer susceptibility genes: a systematic review.
    Breast Cancer Res Treat. 2021 Oct 13. pii: 10.1007/s10549-021-06413.
    PubMed     Abstract available


  96. MERZENICH H, Baaken D, Schmidt M, Bekes I, et al
    Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa).
    Breast Cancer Res Treat. 2021 Oct 9. pii: 10.1007/s10549-021-06412.
    PubMed     Abstract available


  97. HERNANDO-CALVO A, Cescon DW, Bedard PL
    Novel classes of immunotherapy for breast cancer.
    Breast Cancer Res Treat. 2021 Oct 8. pii: 10.1007/s10549-021-06405.
    PubMed     Abstract available


  98. DE LAURENTIIS M, Borstnar S, Campone M, Warner E, et al
    Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
    Breast Cancer Res Treat. 2021 Oct 8. pii: 10.1007/s10549-021-06374.
    PubMed    


  99. VARGAS A, Holub K, Biete A
    Omitting axillary dissection: could we offer a more tailored management to elderly patients with breast cancer?
    Breast Cancer Res Treat. 2021 Oct 5. pii: 10.1007/s10549-021-06404.
    PubMed     Abstract available


  100. BIANCO N, Milano M, Pagan E, Oriecuia C, et al
    Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis.
    Breast Cancer Res Treat. 2021 Oct 5. pii: 10.1007/s10549-021-06407.
    PubMed     Abstract available


  101. HASHIMOTO TAKIGAMI N, Kuniyoshi S, Miki Y, Tamaki K, et al
    Correction to: Breast cancer, diabetes mellitus and glucagonlike peptide1 receptor toward exploring their possible associations.
    Breast Cancer Res Treat. 2021 Oct 4. pii: 10.1007/s10549-021-06380.
    PubMed    


  102. SAVAS P, Salgado R, Loi S
    Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers.
    Breast Cancer Res Treat. 2021;189:599-606.
    PubMed     Abstract available


  103. CHIPIDZA FE, Mushonga M, Kanda C, Chibonda S, et al
    Utilization and predictors of postmastectomy radiation receipt in an Oncology Center in Zimbabwe.
    Breast Cancer Res Treat. 2021;189:701-709.
    PubMed     Abstract available


    September 2021
  104. SOLIMAN O, Lowery A, Kerin M
    Imprecise risk estimation of chemotherapy-related cardiotoxicity in HER2-positive breast cancer using the recently reported societal risk tools.
    Breast Cancer Res Treat. 2021 Sep 29. pii: 10.1007/s10549-021-06403.
    PubMed    


  105. HAQUE R, Chlebowski RT, Chen L
    Sleep medication use and risk of fractures in breast cancer survivors.
    Breast Cancer Res Treat. 2021 Sep 29. pii: 10.1007/s10549-021-06392.
    PubMed     Abstract available


  106. ROCQUE GB, Caston NE, Franks JA, Williams CP, et al
    Clinical trial representativeness and treatment intensity in a real-world sample of women with early stage breast cancer.
    Breast Cancer Res Treat. 2021 Sep 29. pii: 10.1007/s10549-021-06381.
    PubMed     Abstract available


  107. THOREN L, Eriksson M, Lindh JD, Czene K, et al
    Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients.
    Breast Cancer Res Treat. 2021 Sep 27. pii: 10.1007/s10549-021-06386.
    PubMed     Abstract available


  108. LAPIDARI P, Djehal N, Havas J, Gbenou A, et al
    Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue.
    Breast Cancer Res Treat. 2021 Sep 24. pii: 10.1007/s10549-021-06394.
    PubMed     Abstract available


  109. TEINTURIER R, Abou Ziki R, Kassem L, Luo Y, et al
    Reduced menin expression leads to decreased ERalpha expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.
    Breast Cancer Res Treat. 2021 Sep 24. pii: 10.1007/s10549-021-06339.
    PubMed     Abstract available


  110. BAHRAMI N, Jabeen S, Tahiri A, Sauer T, et al
    Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin.
    Breast Cancer Res Treat. 2021 Sep 23. pii: 10.1007/s10549-021-06399.
    PubMed     Abstract available


  111. YANG Y, Pan L, Shao Z
    Trend and survival benefit of contralateral prophylactic mastectomy among men with stage I-III unilateral breast cancer in the USA, 1998-2016.
    Breast Cancer Res Treat. 2021 Sep 23. pii: 10.1007/s10549-021-06397.
    PubMed     Abstract available


  112. FUKADA I, Ito Y, Kondo N, Ohtani S, et al
    A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17).
    Breast Cancer Res Treat. 2021 Sep 23. pii: 10.1007/s10549-021-06396.
    PubMed     Abstract available


  113. DAI MS, Feng YH, Chen SW, Masuda N, et al
    Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two
    Breast Cancer Res Treat. 2021 Sep 23. pii: 10.1007/s10549-021-06313.
    PubMed     Abstract available


  114. MALIN D, Lee Y, Chepikova O, Strekalova E, et al
    Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase.
    Breast Cancer Res Treat. 2021 Sep 22. pii: 10.1007/s10549-021-06398.
    PubMed     Abstract available


  115. CAZZANIGA ME, Vallini I, Montagna E, Amoroso D, et al
    Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.
    Breast Cancer Res Treat. 2021 Sep 21. pii: 10.1007/s10549-021-06375.
    PubMed     Abstract available


  116. ARIAS-PULIDO H, Cimino-Mathews AM, Chaher N, Qualls CR, et al
    Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.
    Breast Cancer Res Treat. 2021 Sep 20. pii: 10.1007/s10549-021-06391.
    PubMed     Abstract available


  117. TEJERA D, Rana M, Basik M, Boileau JF, et al
    Population-based analysis of non-operative management and treatment patterns in older women with estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2021 Sep 20. pii: 10.1007/s10549-021-06393.
    PubMed     Abstract available


  118. VAN BELLE H, Hurvitz SA, Gilbar PJ, Wildiers H, et al
    Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer.
    Breast Cancer Res Treat. 2021 Sep 17. pii: 10.1007/s10549-021-06387.
    PubMed     Abstract available


  119. CAPELLEN CC, Ortega-Rodas J, Morwitzer MJ, Tofilau HMN, et al
    Hyperglycemic conditions proliferate triple negative breast cancer cells: role of ornithine decarboxylase.
    Breast Cancer Res Treat. 2021 Sep 16. pii: 10.1007/s10549-021-06388.
    PubMed     Abstract available


  120. AUGUSTINSSON A, Nilsson MP, Ellberg C, Kristoffersson U, et al
    Genetic testing in women with early-onset breast cancer: a Traceback pilot study.
    Breast Cancer Res Treat. 2021 Sep 16. pii: 10.1007/s10549-021-06351.
    PubMed     Abstract available


  121. HAYNES BP, Schuster G, Buus R, Alataki A, et al
    Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer.
    Breast Cancer Res Treat. 2021 Sep 15. pii: 10.1007/s10549-021-06377.
    PubMed     Abstract available


  122. JIANG R, Sun Y, Chen X, Shi P, et al
    Estrogen-regulated AGR3 activates the estrogen receptor signaling pathway to promote tamoxifen resistance in breast cancer.
    Breast Cancer Res Treat. 2021 Sep 14. pii: 10.1007/s10549-021-06385.
    PubMed     Abstract available


  123. MA SJ, Serra LM, Yu B, Bartl AJ, et al
    Evaluation of risk stratification using gene expression assays in patients with breast cancer receiving neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2021 Sep 14. pii: 10.1007/s10549-021-06269.
    PubMed     Abstract available


  124. DILAWARI A, Rentscher KE, Zhai W, Zhou X, et al
    Medical care disruptions during the first six months of the COVID-19 pandemic: the experience of older breast cancer survivors.
    Breast Cancer Res Treat. 2021 Sep 13. pii: 10.1007/s10549-021-06362.
    PubMed     Abstract available


  125. MOUABBI JA, Osborne CK, Schiff R, Rimawi MF, et al
    Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Sep 13. pii: 10.1007/s10549-021-06383.
    PubMed     Abstract available


  126. GIANNOUDIS A, Sartori A, Eastoe L, Zakaria R, et al
    Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival.
    Breast Cancer Res Treat. 2021 Sep 9. pii: 10.1007/s10549-021-06364.
    PubMed     Abstract available


  127. SUKUMAR JS, Quiroga D, Kassem M, Grimm M, et al
    Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer.
    Breast Cancer Res Treat. 2021 Sep 8. pii: 10.1007/s10549-021-06368.
    PubMed     Abstract available


  128. AUGUSTO TV, Amaral C, Wang Y, Chen S, et al
    Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression.
    Breast Cancer Res Treat. 2021 Sep 8. pii: 10.1007/s10549-021-06376.
    PubMed     Abstract available


  129. WANG X, Zhang L, Zhang X, Luo J, et al
    Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?
    Breast Cancer Res Treat. 2021 Sep 6. pii: 10.1007/s10549-021-06378.
    PubMed     Abstract available


  130. PARK YH, Karantza V, Calhoun SR, Park S, et al
    Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea.
    Breast Cancer Res Treat. 2021 Sep 6. pii: 10.1007/s10549-021-06309.
    PubMed     Abstract available


  131. YE Y, Ma J, Zhang Q, Xiong K, et al
    A CTL/M2 macrophage-related four-gene signature predicting metastasis-free survival in triple-negative breast cancer treated with adjuvant radiotherapy.
    Breast Cancer Res Treat. 2021 Sep 5. pii: 10.1007/s10549-021-06379.
    PubMed     Abstract available


  132. GOLDSTEIN LJ, Mansutti M, Levy C, Chang JC, et al
    A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).
    Breast Cancer Res Treat. 2021 Sep 3. pii: 10.1007/s10549-021-06367.
    PubMed     Abstract available


  133. WIGGINS GAR, Black MA, Dunbier A, Morley-Bunker AE, et al
    Increased gene expression variability in BRCA1-associated and basal-like breast tumours.
    Breast Cancer Res Treat. 2021;189:363-375.
    PubMed     Abstract available


  134. JORGENSEN SF, Andersen B, Lernevall A, Rebolj M, et al
    Variations in pathways and resource use in follow-up after abnormal mammography screening: a nationwide register-based study.
    Breast Cancer Res Treat. 2021;189:551-560.
    PubMed     Abstract available


  135. HAN Y, Lee CT, Xu S, Mi X, et al
    Medication use and mammographic breast density.
    Breast Cancer Res Treat. 2021;189:585-592.
    PubMed     Abstract available


  136. KLECKNER IR, Jusko TA, Culakova E, Chung K, et al
    Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy.
    Breast Cancer Res Treat. 2021;189:521-532.
    PubMed     Abstract available


  137. SIEGEL JB, Mukherjee R, Park Y, Cluver AR, et al
    Prognostic factors for residual occult disease in shave margins during partial mastectomy.
    Breast Cancer Res Treat. 2021;189:471-481.
    PubMed     Abstract available


  138. FUJII T, Masuda H, Cheng YC, Yang F, et al
    A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores.
    Breast Cancer Res Treat. 2021;189:455-461.
    PubMed     Abstract available


  139. COGAN JC, Raghunathan RR, Beauchemin MP, Accordino MK, et al
    New and persistent controlled substance use among patients undergoing mastectomy and reconstructive surgery.
    Breast Cancer Res Treat. 2021;189:445-454.
    PubMed     Abstract available


  140. LIU X, Davis AA, Xie F, Gui X, et al
    Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China.
    Breast Cancer Res Treat. 2021 Sep 1. pii: 10.1007/s10549-021-06370.
    PubMed     Abstract available


    August 2021
  141. TAQI K, Pao JS, Chen L, Ma C, et al
    Immediate breast reconstruction in locally advanced breast cancer: is it safe?
    Breast Cancer Res Treat. 2021 Aug 31. pii: 10.1007/s10549-021-06366.
    PubMed     Abstract available


  142. MOKSUD N, Loo LWM, Yang J, Huang CY, et al
    Cholesterol lowering drug use and breast cancer survival: the Multiethnic Cohort Study.
    Breast Cancer Res Treat. 2021 Aug 30. pii: 10.1007/s10549-021-06360.
    PubMed     Abstract available


  143. ALTHOBITI M, El-Sharawy KA, Joseph C, Aleskandarany M, et al
    Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer.
    Breast Cancer Res Treat. 2021 Aug 28. pii: 10.1007/s10549-021-06336.
    PubMed     Abstract available


  144. TORRISI R, Palumbo R, De Sanctis R, Vici P, et al
    Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9).
    Breast Cancer Res Treat. 2021 Aug 27. pii: 10.1007/s10549-021-06371.
    PubMed     Abstract available


  145. GAL R, Monninkhof EM, van Gils CH, Groenwold RHH, et al
    Effects of exercise in breast cancer patients: implications of the trials within cohorts (TwiCs) design in the UMBRELLA Fit trial.
    Breast Cancer Res Treat. 2021 Aug 24. pii: 10.1007/s10549-021-06363.
    PubMed     Abstract available


  146. XU J, Keenan TE, Overmoyer B, Tung NM, et al
    Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.
    Breast Cancer Res Treat. 2021 Aug 20. pii: 10.1007/s10549-021-06292.
    PubMed     Abstract available


  147. DE LAURENTIIS M, Borstnar S, Campone M, Warner E, et al
    Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
    Breast Cancer Res Treat. 2021 Aug 19. pii: 10.1007/s10549-021-06334.
    PubMed     Abstract available


  148. NADLER MB, Ivers N, Marchand-Austin A, Lofters A, et al
    Patient and provider determinants of breast cancer screening among Ontario women aged 40-49: a population-based retrospective cohort study.
    Breast Cancer Res Treat. 2021 Aug 19. pii: 10.1007/s10549-021-06344.
    PubMed     Abstract available


  149. REAM ME, Walsh EA, Jacobs JM, Taub C, et al
    Brief relaxation training is associated with long-term endocrine therapy adherence among women with breast cancer: post hoc analysis of a randomized controlled trial.
    Breast Cancer Res Treat. 2021 Aug 19. pii: 10.1007/s10549-021-06361.
    PubMed     Abstract available


  150. DE MOURA LEITE L, Cesca MG, Tavares MC, Santana DM, et al
    HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
    Breast Cancer Res Treat. 2021 Aug 18. pii: 10.1007/s10549-021-06365.
    PubMed     Abstract available


  151. ZGODIC A, Eberth JM, Smith BD, Zahnd WE, et al
    Multilevel predictors of guideline concordant needle biopsy use for non-metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Aug 17. pii: 10.1007/s10549-021-06352.
    PubMed     Abstract available


  152. JORDAN VC
    Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team.
    Breast Cancer Res Treat. 2021 Aug 16. pii: 10.1007/s10549-021-06356.
    PubMed     Abstract available


  153. LI H, Song G, Zhou Q, Ran R, et al
    Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Aug 14. pii: 10.1007/s10549-021-06345.
    PubMed     Abstract available


  154. DOUKAS PG, Patel RN, Venkatesh V, Khan SS, et al
    Cardiac risk stratification of breast cancer patients in a cardio-oncology clinic.
    Breast Cancer Res Treat. 2021 Aug 14. pii: 10.1007/s10549-021-06353.
    PubMed     Abstract available


  155. SHEEAN P, Gomez-Perez S, Joyce C, O'Connor P, et al
    Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Aug 13. pii: 10.1007/s10549-021-06358.
    PubMed     Abstract available


  156. ESKANDER MF, Li Y, Bhattacharyya O, Tsung A, et al
    Hormone receptor-positive breast cancer and black race: does sex matter?
    Breast Cancer Res Treat. 2021 Aug 12. pii: 10.1007/s10549-021-06359.
    PubMed     Abstract available


  157. WANG CL, Li JC, Zhou CX, Ma CN, et al
    Long non-coding RNA ARHGAP5-AS1 inhibits migration of breast cancer cell via stabilizing SMAD7 protein.
    Breast Cancer Res Treat. 2021 Aug 9. pii: 10.1007/s10549-021-06286.
    PubMed     Abstract available


  158. REIS J, Thomas O, Lahooti M, Lyngra M, et al
    Correlation between MRI morphological response patterns and histopathological tumor regression after neoadjuvant endocrine therapy in locally advanced breast cancer: a randomized phase II trial.
    Breast Cancer Res Treat. 2021 Aug 6. pii: 10.1007/s10549-021-06343.
    PubMed     Abstract available


  159. HANNOUN-LEVI JM, Polgar C, Strnad V
    In regard to Van den Bruele AB et al. Management of ipsilateral breast tumor recurrence following breast conservation surgery: a comparative study of re-conservation vs mastectomy. Breast Cancer Res Treat. 2021 May;187(1):105-112. doi:10.1007/s10549-0
    Breast Cancer Res Treat. 2021 Aug 6. pii: 10.1007/s10549-021-06348.
    PubMed    


  160. LIM SZ, Kusumawidjaja G, Mohd Ishak HM, Tan BKT, et al
    Outcomes of Stage I and II Breast Cancer with Nodal Micrometastases Treated with Mastectomy without Axillary Therapy.
    Breast Cancer Res Treat. 2021 Aug 3. pii: 10.1007/s10549-021-06341.
    PubMed     Abstract available


  161. FRIEBEL-KLINGNER TM, Ehsan S, Conant EF, Kontos D, et al
    Risk factors for breast cancer subtypes among Black women undergoing screening mammography.
    Breast Cancer Res Treat. 2021 Aug 3. pii: 10.1007/s10549-021-06340.
    PubMed     Abstract available


  162. VOLKEL V, Hueting TA, Draeger T, van Maaren MC, et al
    Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model.
    Breast Cancer Res Treat. 2021 Aug 2. pii: 10.1007/s10549-021-06335.
    PubMed     Abstract available


  163. LAISH I, Friedman E, Levi-Reznick G, Kedar I, et al
    Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.
    Breast Cancer Res Treat. 2021;188:685-694.
    PubMed     Abstract available


  164. SATO S, Maki S, Yamanaka T, Hoshino D, et al
    Machine learning-based image analysis for accelerating the diagnosis of complicated preneoplastic and neoplastic ductal lesions in breast biopsy tissues.
    Breast Cancer Res Treat. 2021;188:649-659.
    PubMed     Abstract available


  165. WEITZEL JN, Kidd J, Bernhisel R, Shehayeb S, et al
    Multigene assessment of genetic risk for women for two or more breast cancers.
    Breast Cancer Res Treat. 2021;188:759-768.
    PubMed     Abstract available


  166. TANG A, Cohan CM, Hansen KS, Beattie G, et al
    Relationship between body mass index and malignancy rates of MRI-guided breast biopsies: impact of clinicodemographic factors.
    Breast Cancer Res Treat. 2021;188:739-747.
    PubMed     Abstract available


  167. RUDDY KJ, Zheng Y, Tayob N, Hu J, et al
    Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
    Breast Cancer Res Treat. 2021;189:103-110.
    PubMed     Abstract available


  168. SANCHEZ TR, Genkinger JM, Lacey JV Jr
    Sanchez et al. respond to Austin-Datta et al.
    Breast Cancer Res Treat. 2021;188:827-828.
    PubMed    


  169. WANG Y, van den Broek AJ, Schmidt MK
    Letter to the editor regarding: 'Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis'.
    Breast Cancer Res Treat. 2021;188:821-823.
    PubMed    


    July 2021
  170. REID S, Haddad D, Tezak A, Weidner A, et al
    Impact of molecular subtype and race on HR+, HER2- breast cancer survival.
    Breast Cancer Res Treat. 2021 Jul 31. pii: 10.1007/s10549-021-06342.
    PubMed     Abstract available


  171. HANNA A, Balko JM
    Breast cancer resistance mechanisms: challenges to immunotherapy.
    Breast Cancer Res Treat. 2021 Jul 28. pii: 10.1007/s10549-021-06337.
    PubMed     Abstract available


  172. JERZAK KJ, Lipton N, Nofech-Mozes S, Boles D, et al
    Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study.
    Breast Cancer Res Treat. 2021 Jul 27. pii: 10.1007/s10549-021-06327.
    PubMed     Abstract available


  173. EVANS DG, Howell SJ, Gandhi A, van Veen EM, et al
    Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women.
    Breast Cancer Res Treat. 2021 Jul 26. pii: 10.1007/s10549-021-06333.
    PubMed     Abstract available


  174. BALCH SM, Vaz-Luis I, Li T, Tayob N, et al
    A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast ca
    Breast Cancer Res Treat. 2021 Jul 24. pii: 10.1007/s10549-021-06329.
    PubMed     Abstract available


  175. JEON YW, Park HS, Ko Y, Sung YS, et al
    Intermuscular fat density as a novel prognostic factor in breast cancer patients treated with adjuvant chemotherapy.
    Breast Cancer Res Treat. 2021 Jul 20. pii: 10.1007/s10549-021-06322.
    PubMed     Abstract available


  176. LEI L, Chan HC, Lu TP, Cheng SH, et al
    Risk evaluation of early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients: a population-based study from Taiwan.
    Breast Cancer Res Treat. 2021 Jul 19. pii: 10.1007/s10549-021-06330.
    PubMed     Abstract available


  177. ALFARSI LH, El Ansari R, Craze ML, Mohammed OJ, et al
    SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2021 Jul 19. pii: 10.1007/s10549-021-06298.
    PubMed     Abstract available


  178. BATENBURG MCT, Maarse W, van der Leij F, Baas IO, et al
    The impact of hyperbaric oxygen therapy on late radiation toxicity and quality of life in breast cancer patients.
    Breast Cancer Res Treat. 2021 Jul 19. pii: 10.1007/s10549-021-06332.
    PubMed     Abstract available


  179. DENT R, Oliveira M, Isakoff SJ, Im SA, et al
    Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.
    Breast Cancer Res Treat. 2021 Jul 15. pii: 10.1007/s10549-021-06143.
    PubMed     Abstract available


  180. BOTTY VAN DEN BRUELE A, Ferraro E, Sevilimedu V, Hogan MP, et al
    Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy?
    Breast Cancer Res Treat. 2021 Jul 14. pii: 10.1007/s10549-021-06331.
    PubMed     Abstract available


  181. BEKELE BM, Luijendijk M, Schagen SB, de Ruiter M, et al
    Fatigue and resting-state functional brain networks in breast cancer patients treated with chemotherapy.
    Breast Cancer Res Treat. 2021 Jul 14. pii: 10.1007/s10549-021-06326.
    PubMed     Abstract available


  182. WALBAUM B, Puschel K, Medina L, Merino T, et al
    Screen-detected breast cancer is associated with better prognosis and survival compared to self-detected/symptomatic cases in a Chilean cohort of female patients.
    Breast Cancer Res Treat. 2021 Jul 10. pii: 10.1007/s10549-021-06317.
    PubMed     Abstract available


  183. YAN CH, Coleman C, Nabulsi NA, Chiu BC, et al
    Associations between frailty and cancer-specific mortality among older women with breast cancer.
    Breast Cancer Res Treat. 2021 Jul 9. pii: 10.1007/s10549-021-06323.
    PubMed     Abstract available


  184. PARK J, Tacam MJ, Chauhan G, Cohen EN, et al
    Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression.
    Breast Cancer Res Treat. 2021 Jul 9. pii: 10.1007/s10549-021-06316.
    PubMed     Abstract available


  185. COUGHLIN SS, Ayyala DN
    Symptoms associated with comorbid diabetes among breast cancer survivors.
    Breast Cancer Res Treat. 2021 Jul 9. pii: 10.1007/s10549-021-06324.
    PubMed     Abstract available


  186. LIU X, Qiu R, Xu M, Meng M, et al
    KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.
    Breast Cancer Res Treat. 2021 Jul 8. pii: 10.1007/s10549-021-06325.
    PubMed     Abstract available


  187. WALLNER LP, Abrahamse P, Gargaro JG, Radhakrishnan A, et al
    Improving the delivery of team-based survivorship care after primary breast cancer treatment through a multi-level intervention: a pilot randomized controlled trial.
    Breast Cancer Res Treat. 2021 Jul 7. pii: 10.1007/s10549-021-06257.
    PubMed     Abstract available


  188. BURKS HE, Matossian MD, Rhodes LV, Phamduy T, et al
    ZEB2 regulates endocrine therapy sensitivity and metastasis in luminal a breast cancer cells through a non-canonical mechanism.
    Breast Cancer Res Treat. 2021 Jul 6. pii: 10.1007/s10549-021-06256.
    PubMed     Abstract available


  189. KIM JY, Jeon E, Kwon S, Jung H, et al
    Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer.
    Breast Cancer Res Treat. 2021 Jul 5. pii: 10.1007/s10549-021-06310.
    PubMed     Abstract available


  190. BENGTSSON Y, Sandsveden M, Borgquist S, Manjer J, et al
    Serum zinc and dietary intake of zinc in relation to risk of different breast cancer subgroups and serum levels as a marker of intake: a prospective nested case-control study.
    Breast Cancer Res Treat. 2021 Jul 5. pii: 10.1007/s10549-021-06318.
    PubMed     Abstract available


  191. SHARMA U, Medina-Saenz K, Miller PC, Troness B, et al
    Heterotypic clustering of circulating tumor cells and circulating cancer-associated fibroblasts facilitates breast cancer metastasis.
    Breast Cancer Res Treat. 2021 Jul 3. pii: 10.1007/s10549-021-06299.
    PubMed     Abstract available


  192. JACOBS DHM, Charaghvandi RK, Horeweg N, Maduro JH, et al
    Health-related quality of life of early-stage breast cancer patients after different radiotherapy regimens.
    Breast Cancer Res Treat. 2021 Jul 3. pii: 10.1007/s10549-021-06314.
    PubMed     Abstract available


  193. POLLEY MC, Dickler MN, Sinnwell J, Tenner K, et al
    A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy.
    Breast Cancer Res Treat. 2021 Jul 3. pii: 10.1007/s10549-021-06319.
    PubMed     Abstract available


  194. MCGUINNESS JE, Altoe ML, Marone A, Franks LE, et al
    Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer.
    Breast Cancer Res Treat. 2021 Jul 2. pii: 10.1007/s10549-021-06320.
    PubMed     Abstract available


  195. CASTELO M, Brown Z, D'Abbondanza JA, Wasilewski NV, et al
    Psychological consequences of MRI-based screening among women with strong family histories of breast cancer.
    Breast Cancer Res Treat. 2021 Jul 2. pii: 10.1007/s10549-021-06300.
    PubMed     Abstract available


  196. KEARNEY MR, McGuinness JE, Kalinsky K
    Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancer.
    Breast Cancer Res Treat. 2021 Jul 2. pii: 10.1007/s10549-021-06291.
    PubMed     Abstract available


  197. HASHIMOTO TAKIGAMI N, Kuniyoshi S, Miki Y, Tamaki K, et al
    Breast Cancer, Diabetes Mellitus and Glucagon-Like Peptide-1 Receptor Toward Exploring Their Possible Associations.
    Breast Cancer Res Treat. 2021 Jul 2. pii: 10.1007/s10549-021-06288.
    PubMed     Abstract available


  198. MATOSSIAN MD, Elliott S, Van Hoang T, Burks HE, et al
    NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells.
    Breast Cancer Res Treat. 2021 Jul 1. pii: 10.1007/s10549-021-06295.
    PubMed     Abstract available


  199. REN M, Orozco A, Shao K, Albanez A, et al
    Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer.
    Breast Cancer Res Treat. 2021 Jul 1. pii: 10.1007/s10549-021-06305.
    PubMed     Abstract available


  200. AL-KAWAZ A, Miligy IM, Toss MS, Mohammed OJ, et al
    The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ.
    Breast Cancer Res Treat. 2021;188:53-63.
    PubMed     Abstract available


  201. DEMPSEY N, Rosenthal A, Dabas N, Kropotova Y, et al
    Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
    Breast Cancer Res Treat. 2021;188:21-36.
    PubMed     Abstract available


  202. SUNDARESAN TK, Dubash TD, Zheng Z, Bardia A, et al
    Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.
    Breast Cancer Res Treat. 2021;188:43-52.
    PubMed     Abstract available


  203. BOYER JZ, Phillips GDL, Nitta H, Garsha K, et al
    Activity of trastuzumab emtansine (T-DM1) in 3D cell culture.
    Breast Cancer Res Treat. 2021;188:65-75.
    PubMed     Abstract available


  204. AROLE V, Nitta H, Wei L, Shen T, et al
    M2 tumor-associated macrophages play important role in predicting response to neoadjuvant chemotherapy in triple-negative breast carcinoma.
    Breast Cancer Res Treat. 2021;188:37-42.
    PubMed     Abstract available


  205. RAKOVITCH E, Parpia S, Koch A, Grimard L, et al
    DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS.
    Breast Cancer Res Treat. 2021;188:133-139.
    PubMed     Abstract available


  206. HABIBI M, Prasath V, Dembinski R, Sacks JM, et al
    Comparison of mastectomy and breast reconstruction outcomes using low thermal dissection versus traditional electrocautery: a blinded randomized trial.
    Breast Cancer Res Treat. 2021;188:101-106.
    PubMed     Abstract available


  207. LERTWILAIWITTAYA P, Roothumnong E, Nakthong P, Dungort P, et al
    Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.
    Breast Cancer Res Treat. 2021;188:237-248.
    PubMed     Abstract available


  208. MUNOZ-MONTANO WR, Cabrera-Galeana P, De la Garza-Ramos C, Azim HA Jr, et al
    Prognosis of breast cancer diagnosed during pregnancy and early postpartum according to immunohistochemical subtype: A matched case-control study.
    Breast Cancer Res Treat. 2021;188:489-500.
    PubMed     Abstract available


    June 2021
  209. LOPES CARDOZO JMN, Schmidt MK, van 't Veer LJ, Cardoso F, et al
    Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer.
    Breast Cancer Res Treat. 2021 Jun 30. pii: 10.1007/s10549-021-06315.
    PubMed     Abstract available


  210. ABUBAKAR M, Guo C, Koka H, Zhu B, et al
    Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer.
    Breast Cancer Res Treat. 2021 Jun 29. pii: 10.1007/s10549-021-06294.
    PubMed     Abstract available


  211. JOHNSON JE, Strassle PD, de Oliveira GC, Agala CB, et al
    Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients.
    Breast Cancer Res Treat. 2021 Jun 26. pii: 10.1007/s10549-021-06303.
    PubMed     Abstract available


  212. FILIPE MD, Siesling S, Vriens MR, van Diest P, et al
    The association of socioeconomic status on treatment strategy in patients with stage I and II breast cancer in the Netherlands.
    Breast Cancer Res Treat. 2021 Jun 26. pii: 10.1007/s10549-021-06308.
    PubMed     Abstract available


  213. ADEMUYIWA FO, Chen I, Luo J, Rimawi MF, et al
    Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
    Breast Cancer Res Treat. 2021 Jun 26. pii: 10.1007/s10549-021-06307.
    PubMed     Abstract available


  214. KEARNEY M, Franks L, Lee S, Tiersten A, et al
    Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.
    Breast Cancer Res Treat. 2021 Jun 24. pii: 10.1007/s10549-021-06306.
    PubMed     Abstract available


  215. HAN X, Duan X, Liu Z, Long Y, et al
    ZEB1 directly inhibits GPX4 transcription contributing to ROS accumulation in breast cancer cells.
    Breast Cancer Res Treat. 2021 Jun 24. pii: 10.1007/s10549-021-06301.
    PubMed     Abstract available


  216. BALIJA TM, Braz D, Hyman S, Montgomery LL, et al
    Early reflector localization improves the accuracy of localization and excision of a previously positive axillary lymph node following neoadjuvant chemotherapy in patients with breast cancer.
    Breast Cancer Res Treat. 2021 Jun 23. pii: 10.1007/s10549-021-06281.
    PubMed     Abstract available


  217. COLE KM, Clemons M, Alzahrani M, Larocque G, et al
    Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers.
    Breast Cancer Res Treat. 2021 Jun 22. pii: 10.1007/s10549-021-06186.
    PubMed     Abstract available


  218. KO G, Hota S, Cil TD
    COVID-19 vaccination and breast cancer surgery timing.
    Breast Cancer Res Treat. 2021 Jun 22. pii: 10.1007/s10549-021-06293.
    PubMed     Abstract available


  219. KIM H, Kim YJ, Park D, Park WY, et al
    Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study.
    Breast Cancer Res Treat. 2021 Jun 21. pii: 10.1007/s10549-021-06296.
    PubMed     Abstract available


  220. STEBBING J, Baranau YV, Baryash V, Manikhas A, et al
    Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
    Breast Cancer Res Treat. 2021 Jun 20. pii: 10.1007/s10549-021-06240.
    PubMed     Abstract available


  221. REYNA C, Johnston ME, Morris MC, Lee TC, et al
    National trends for axillary lymph node dissection and survival outcomes for clinical T3/T4 node-negative breast cancer patients undergoing mastectomy with positive lymph nodes.
    Breast Cancer Res Treat. 2021 Jun 18. pii: 10.1007/s10549-021-06290.
    PubMed     Abstract available


  222. LIVINGSTON-ROSANOFF D, Trentham-Dietz A, Hampton JM, Newcomb PA, et al
    Does margin width impact breast cancer recurrence rates in women with breast conserving surgery for ductal carcinoma in situ?
    Breast Cancer Res Treat. 2021 Jun 15. pii: 10.1007/s10549-021-06278.
    PubMed     Abstract available


  223. PRIOR L, O'Dwyer R, Farooq AR, Greally M, et al
    Pregnancy-associated breast cancer: evaluating maternal and foetal outcomes. A national study.
    Breast Cancer Res Treat. 2021 Jun 14. pii: 10.1007/s10549-021-06263.
    PubMed     Abstract available


  224. RUGO HS, Pennella EJ, Gopalakrishnan U, Hernandez-Bronchud M, et al
    Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Jun 14. pii: 10.1007/s10549-021-06197.
    PubMed     Abstract available


  225. PUMPALOVA YS, Ayeni OA, Chen WC, O'Neil DS, et al
    Impact of HIV infection on overall survival among women with stage IV breast cancer in South Africa.
    Breast Cancer Res Treat. 2021 Jun 14. pii: 10.1007/s10549-021-06265.
    PubMed     Abstract available


  226. SKARPING I, Fornvik D, Zackrisson S, Borgquist S, et al
    Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer.
    Breast Cancer Res Treat. 2021 Jun 12. pii: 10.1007/s10549-021-06283.
    PubMed     Abstract available


  227. ALMODALLAL Y, Le-Rademacher JG, Cook KD, Yadav S, et al
    Observations with alpelisib in older patients (>/= 65 year of age) with breast cancer in a non-clinical trial setting.
    Breast Cancer Res Treat. 2021 Jun 12. pii: 10.1007/s10549-021-06277.
    PubMed     Abstract available


  228. MORIKAWA A, Grkovski M, Patil S, Jhaveri KL, et al
    A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging.
    Breast Cancer Res Treat. 2021 Jun 10. pii: 10.1007/s10549-021-06209.
    PubMed     Abstract available


  229. DAMIN AP
    Reply to the letter on sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer.
    Breast Cancer Res Treat. 2021 Jun 8. pii: 10.1007/s10549-021-06285.
    PubMed    


  230. CAINI S, Fiorito G, Palli D, Bendinelli B, et al
    Pre-diagnostic DNA methylation patterns differ according to mammographic breast density amongst women who subsequently develop breast cancer: a case-only study in the EPIC-Florence cohort.
    Breast Cancer Res Treat. 2021 Jun 8. pii: 10.1007/s10549-021-06273.
    PubMed     Abstract available


  231. NTELIOPOULOS G, Page K, Hills A, Howarth K, et al
    Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients.
    Breast Cancer Res Treat. 2021 Jun 7. pii: 10.1007/s10549-021-06220.
    PubMed     Abstract available


  232. SZUHANY KL, Malgaroli M, Riley G, Miron CD, et al
    Barriers and engagement in breast cancer survivorship wellness activities.
    Breast Cancer Res Treat. 2021 Jun 7. pii: 10.1007/s10549-021-06279.
    PubMed     Abstract available


  233. BROWN JC, Sarwer DB, Troxel AB, Sturgeon K, et al
    A randomized trial of exercise and diet on body composition in survivors of breast cancer with overweight or obesity.
    Breast Cancer Res Treat. 2021 Jun 5. pii: 10.1007/s10549-021-06284.
    PubMed     Abstract available


  234. ORTEGA EXPOSITO C, Falo C, Pernas S, Perez Carton S, et al
    The effect of omitting axillary dissection and the impact of radiotherapy on patients with breast cancer sentinel node macrometastases: a cohort study following the ACOSOG Z0011 and AMAROS trials.
    Breast Cancer Res Treat. 2021 Jun 4. pii: 10.1007/s10549-021-06274.
    PubMed     Abstract available


  235. LOPRESTI ML, Bian JJ, Sakr BJ, Strenger RS, et al
    Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study.
    Breast Cancer Res Treat. 2021 Jun 4. pii: 10.1007/s10549-021-06266.
    PubMed     Abstract available


  236. DIFLORIO-ALEXANDER RM, Song Q, Dwan D, Austin-Strohbehn JA, et al
    Fat-enlarged axillary lymph nodes are associated with node-positive breast cancer in obese patients.
    Breast Cancer Res Treat. 2021 Jun 3. pii: 10.1007/s10549-021-06262.
    PubMed     Abstract available


  237. HAGIWARA Y, Sawaki M, Uemura Y, Kawahara T, et al
    Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial.
    Breast Cancer Res Treat. 2021 Jun 2. pii: 10.1007/s10549-021-06253.
    PubMed     Abstract available


  238. SAINI G, Gogineni K, Kittles RA, Aneja R, et al
    Undercutting efforts of precision medicine: roadblocks to minority representation in breast cancer clinical trials.
    Breast Cancer Res Treat. 2021 Jun 2. pii: 10.1007/s10549-021-06264.
    PubMed     Abstract available


  239. SHAH AN, Carroll KJ, Gerratana L, Lin C, et al
    Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer.
    Breast Cancer Res Treat. 2021;187:397-405.
    PubMed     Abstract available


  240. MORENO G, Molina M, Wu R, Sullivan JR, et al
    Unveiling the histopathologic spectrum of MRI-guided breast biopsies: an institutional pathological-radiological correlation.
    Breast Cancer Res Treat. 2021;187:673-680.
    PubMed     Abstract available


  241. FEGHHI M, Rezaie J, Mostafanezhad K, Jabbari N, et al
    Bystander effects induced by electron beam-irradiated MCF-7 cells: a potential mechanism of therapy resistance.
    Breast Cancer Res Treat. 2021;187:657-671.
    PubMed     Abstract available


  242. SWARNKAR PK, Mokbel K
    Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.
    Breast Cancer Res Treat. 2021;187:919-920.
    PubMed    


  243. GAO Y, Wu N, Wang S, Yang X, et al
    Concurrent mutations associated with trastuzumab-resistance revealed by single cell sequencing.
    Breast Cancer Res Treat. 2021;187:613-624.
    PubMed     Abstract available


  244. AUSTIN-DATTA RJ, Smotherman CR, Yaghjyan L
    Association between rice consumption and risk of cancer incidence in the California Teachers Study.
    Breast Cancer Res Treat. 2021;187:917-918.
    PubMed    


  245. TSANG JY, Lai ST, Ni YB, Shao Y, et al
    SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast.
    Breast Cancer Res Treat. 2021;187:339-347.
    PubMed     Abstract available


  246. PATEL B, Merker L, Sahu A
    Letter to the editor regarding: 'Impalpable breast lesion localisation, a logistical challenge: results of the UK iBRA-NET national practice questionnaire'.
    Breast Cancer Res Treat. 2021;187:601-602.
    PubMed    


  247. SALVIAT F, Charles C, Uzan C
    Shall patients' anxiety influence surgical decisions for atypical breast lesions? A substudy of the prospective NOMAT trial.
    Breast Cancer Res Treat. 2021;187:597-599.
    PubMed    


  248. STOEN E, Kagihara J, Shagisultanova E, Fisher CM, et al
    Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval.
    Breast Cancer Res Treat. 2021;187:883-891.
    PubMed     Abstract available


  249. LO GULLO R, Vincenti K, Rossi Saccarelli C, Gibbs P, et al
    Diagnostic value of radiomics and machine learning with dynamic contrast-enhanced magnetic resonance imaging for patients with atypical ductal hyperplasia in predicting malignant upgrade.
    Breast Cancer Res Treat. 2021;187:535-545.
    PubMed     Abstract available


    May 2021
  250. BERNHARDT SM, Dasari P, Glynn DJ, Townsend AR, et al
    Comparison of hormone-induced mRNA and protein biomarker expression changes in breast cancer cells.
    Breast Cancer Res Treat. 2021 May 31. pii: 10.1007/s10549-021-06254.
    PubMed     Abstract available


  251. DIBBLE KE, Baumgartner RN, Boone SD, Baumgartner KB, et al
    Physical activity, ethnicity, and quality of life among breast cancer survivors and population-based controls: the long-term quality of life follow-up study.
    Breast Cancer Res Treat. 2021 May 29. pii: 10.1007/s10549-021-06261.
    PubMed     Abstract available


  252. TRAPANI D, Giugliano F, Uliano J, Zia VAA, et al
    Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review.
    Breast Cancer Res Treat. 2021 May 27. pii: 10.1007/s10549-021-06259.
    PubMed     Abstract available


  253. HARATI R, Mabondzo A, Tlili A, Khoder G, et al
    Combinatorial targeting of microRNA-26b and microRNA-101 exerts a synergistic inhibition on cyclooxygenase-2 in brain metastatic triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2021 May 26. pii: 10.1007/s10549-021-06255.
    PubMed     Abstract available


  254. MILLER MM, Meneveau MO, Rochman CM, Schroen AT, et al
    Impact of the COVID-19 pandemic on breast cancer screening volumes and patient screening behaviors.
    Breast Cancer Res Treat. 2021 May 25. pii: 10.1007/s10549-021-06252.
    PubMed     Abstract available


  255. JOOSEN MEM, Schop SJ, Reinhoudt LL, van Kuijk SMJ, et al
    The difference in local, regional and distant breast cancer recurrence between the immediate and delayed DIEP flap procedure; a retrospective cohort study.
    Breast Cancer Res Treat. 2021 May 24. pii: 10.1007/s10549-021-06199.
    PubMed     Abstract available


  256. DELRIEU L, Martin A, Touillaud M, Perol O, et al
    Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer: results from the ABLE feasibility trial.
    Breast Cancer Res Treat. 2021 May 19. pii: 10.1007/s10549-021-06238.
    PubMed     Abstract available


  257. ZHOU Y, Xu Y, Wang C, Gong Y, et al
    Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.
    Breast Cancer Res Treat. 2021 May 18. pii: 10.1007/s10549-021-06247.
    PubMed     Abstract available


  258. EUSTACE AJ, Madden SF, Fay J, Collins DM, et al
    The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.
    Breast Cancer Res Treat. 2021 May 13. pii: 10.1007/s10549-021-06244.
    PubMed     Abstract available


  259. ARJMANDI F, Mootz A, Farr D, Reddy S, et al
    New horizons in imaging and surgical assessment of breast cancer lymph node metastasis.
    Breast Cancer Res Treat. 2021 May 12. pii: 10.1007/s10549-021-06248.
    PubMed     Abstract available


  260. ZHU Q, Ademuyiwa FO, Young C, Appleton C, et al
    Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography.
    Breast Cancer Res Treat. 2021 May 10. pii: 10.1007/s10549-021-06239.
    PubMed     Abstract available


  261. CHUN JW, Kim J, Chung IIY, Ko BS, et al
    Comparison of survival outcomes for axillary surgery extent based on intraoperative sentinel lymph node biopsy result after neoadjuvant chemotherapy for breast cancer.
    Breast Cancer Res Treat. 2021 May 8. pii: 10.1007/s10549-021-06249.
    PubMed     Abstract available


  262. WATANABE J, Mitsuya K, Nakamoto S, Harada H, et al
    Leptomeningeal Metastasis in ER + HER2- Advanced Breast Cancer Patients: A Review of the Cases in a Single Institute Over a 15-year Period.
    Breast Cancer Res Treat. 2021 May 8. pii: 10.1007/s10549-021-06246.
    PubMed     Abstract available


  263. KUMAR S, Bal A, Das A, Loriya I, et al
    Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.
    Breast Cancer Res Treat. 2021 May 5. pii: 10.1007/s10549-021-06242.
    PubMed     Abstract available


  264. SWARNKAR PK, Mokbel K
    Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
    Breast Cancer Res Treat. 2021 May 5. pii: 10.1007/s10549-021-06222.
    PubMed    


  265. TAN EH, Wong ALA, Tan CC, Wong P, et al
    Facilitators and barriers to medication adherence with adjuvant endocrine therapy in women with breast cancer: a structural equation modelling approach.
    Breast Cancer Res Treat. 2021 May 4. pii: 10.1007/s10549-021-06204.
    PubMed     Abstract available


  266. GROEN EJ, van der Noordaa MEM, Schaapveld M, Sonke GS, et al
    Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.
    Breast Cancer Res Treat. 2021 May 4. pii: 10.1007/s10549-021-06235.
    PubMed     Abstract available


  267. SILVA SN, Gomes BC, Andre S, Felix A, et al
    Male and female breast cancer: the two faces of the same genetic susceptibility coin.
    Breast Cancer Res Treat. 2021 May 3. pii: 10.1007/s10549-021-06159.
    PubMed     Abstract available


  268. SIEGEL EL, Whiting J, Kim Y, Sun W, et al
    Effect of surgical complications on outcomes in breast cancer patients treated with mastectomy and immediate reconstruction.
    Breast Cancer Res Treat. 2021 May 3. pii: 10.1007/s10549-021-06241.
    PubMed     Abstract available


  269. MCLEMORE LE, Albarracin CT, Gruschkus SK, Bassett RL Jr, et al
    HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines.
    Breast Cancer Res Treat. 2021;187:95-104.
    PubMed     Abstract available


  270. HUANG S, Houssami N, Brennan M, Nickel B, et al
    The impact of mandatory mammographic breast density notification on supplemental screening practice in the United States: a systematic review.
    Breast Cancer Res Treat. 2021;187:11-30.
    PubMed     Abstract available


  271. DEL VALLE DD, Pardo JA, Maselli AM, Valero MG, et al
    Evaluation of online Spanish and English health materials for preventive mastectomy. are we providing adequate information?
    Breast Cancer Res Treat. 2021;187:1-9.
    PubMed     Abstract available


  272. VAN DEN BRUELE AB, Chen I, Sevilimedu V, Le T, et al
    Management of ipsilateral breast tumor recurrence following breast conservation surgery: a comparative study of re-conservation vs mastectomy.
    Breast Cancer Res Treat. 2021;187:105-112.
    PubMed     Abstract available


  273. ALANKO J, Tanner M, Vanninen R, Auvinen A, et al
    Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis.
    Breast Cancer Res Treat. 2021;187:267-274.
    PubMed     Abstract available


  274. THEBERGE I, Vandal N, Perron L, Guertin MH, et al
    Association between radiologists' and facilities' characteristics and mammography screening detection of ductal carcinoma in situ.
    Breast Cancer Res Treat. 2021;187:255-266.
    PubMed     Abstract available


  275. BYNG D, Retel VP, Schaapveld M, Wesseling J, et al
    Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
    Breast Cancer Res Treat. 2021;187:187-196.
    PubMed     Abstract available


  276. LUITEN JD, Luiten EJT, van der Sangen MJC, Vreuls W, et al
    Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands.
    Breast Cancer Res Treat. 2021;187:245-254.
    PubMed     Abstract available


    April 2021
  277. VIDULA N, Yau C, Rugo HS
    Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer.
    Breast Cancer Res Treat. 2021 Apr 28. pii: 10.1007/s10549-021-06234.
    PubMed     Abstract available


  278. MOY B, Oliveira M, Saura C, Gradishar W, et al
    Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and >/= 2 prior HER2-directed regimens.
    Breast Cancer Res Treat. 2021 Apr 28. pii: 10.1007/s10549-021-06217.
    PubMed     Abstract available


  279. KAZMI S, Chatterjee D, Raju D, Hauser R, et al
    Correction to: Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
    Breast Cancer Res Treat. 2021 Apr 27. pii: 10.1007/s10549-021-06223.
    PubMed    


  280. LEONARDI MC, Scognamiglio IR, Maisonneuve P, Dicuonzo S, et al
    Mastectomy alone for pT1-2 pN0-1 breast cancer patients: when postmastectomy radiotherapy is indicated.
    Breast Cancer Res Treat. 2021 Apr 27. pii: 10.1007/s10549-021-06227.
    PubMed     Abstract available


  281. WANG Z, Liu J, Ma F, Wang J, et al
    Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial.
    Breast Cancer Res Treat. 2021 Apr 25. pii: 10.1007/s10549-021-06216.
    PubMed     Abstract available


  282. GRUSLOVA A, McClellan B, Balinda HU, Viswanadhapalli S, et al
    FASN inhibition as a potential treatment for endocrine-resistant breast cancer.
    Breast Cancer Res Treat. 2021 Apr 24. pii: 10.1007/s10549-021-06231.
    PubMed     Abstract available


  283. BHARDWAJ A, Embury MD, Rojo RD, Albarracin C, et al
    Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer.
    Breast Cancer Res Treat. 2021 Apr 24. pii: 10.1007/s10549-021-06229.
    PubMed     Abstract available


  284. LEONE JP, Vallejo CT, Hassett MJ, Leone J, et al
    Factors associated with late risks of breast cancer-specific mortality in the SEER registry.
    Breast Cancer Res Treat. 2021 Apr 24. pii: 10.1007/s10549-021-06233.
    PubMed     Abstract available


  285. KOH M, Jung J, Kim SS, Do Ahn S, et al
    Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2021 Apr 23. pii: 10.1007/s10549-021-06228.
    PubMed     Abstract available


  286. STROJNIK K, Krajc M, Dragos VS, Stegel V, et al
    Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A > G founder variant could be associated with higher male breast cancer risk.
    Breast Cancer Res Treat. 2021 Apr 23. pii: 10.1007/s10549-021-06224.
    PubMed     Abstract available


  287. VERON L, Wehrer D, Annerose-Zephir G, Suciu V, et al
    Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up.
    Breast Cancer Res Treat. 2021 Apr 23. pii: 10.1007/s10549-021-06226.
    PubMed     Abstract available


  288. LEPROUX C, Seegers V, Patsouris A, Sauterey B, et al
    Success and risks of pregnancy after breast cancer.
    Breast Cancer Res Treat. 2021 Apr 21. pii: 10.1007/s10549-021-06232.
    PubMed     Abstract available


  289. CHEN M, Zhao Y, Yang X, Zhao Y, et al
    NSDHL promotes triple-negative breast cancer metastasis through the TGFbeta signaling pathway and cholesterol biosynthesis.
    Breast Cancer Res Treat. 2021 Apr 16. pii: 10.1007/s10549-021-06213.
    PubMed     Abstract available


  290. HUANG CS, Yang Y, Kwong A, Chen SC, et al
    Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.
    Breast Cancer Res Treat. 2021 Apr 15. pii: 10.1007/s10549-021-06166.
    PubMed     Abstract available


  291. KOCA E, Niravath PA, Ensor J, Patel TA, et al
    ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer.
    Breast Cancer Res Treat. 2021 Apr 15. pii: 10.1007/s10549-021-06214.
    PubMed     Abstract available


  292. HEQUET D, Harrissart G, Krief D, Maumy L, et al
    Prosigna test in breast cancer: real-life experience.
    Breast Cancer Res Treat. 2021 Apr 15. pii: 10.1007/s10549-021-06191.
    PubMed     Abstract available


  293. SALEH B, Elhawary MA, Mohamed ME, Ali IN, et al
    Gail model utilization in predicting breast cancer risk in Egyptian women: a cross-sectional study.
    Breast Cancer Res Treat. 2021 Apr 14. pii: 10.1007/s10549-021-06200.
    PubMed     Abstract available


  294. HADDAD TC, He J, O'Sullivan CC, Chen B, et al
    Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).
    Breast Cancer Res Treat. 2021 Apr 14. pii: 10.1007/s10549-021-06221.
    PubMed     Abstract available


  295. PAI T, Cornell L, Seneviratne D, Niazi S, et al
    Pre-diagnosis major life stressors and breast cancer outcomes.
    Breast Cancer Res Treat. 2021 Apr 12. pii: 10.1007/s10549-021-06218.
    PubMed     Abstract available


  296. HOPSON MB, Lee S, Accordino M, Trivedi M, et al
    Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer.
    Breast Cancer Res Treat. 2021 Apr 10. pii: 10.1007/s10549-021-06210.
    PubMed     Abstract available


  297. KEELAN S, Heeney A, Downey E, Hegarty A, et al
    Breast cancer patients with a negative axillary ultrasound may have clinically significant nodal metastasis.
    Breast Cancer Res Treat. 2021 Apr 10. pii: 10.1007/s10549-021-06194.
    PubMed     Abstract available


  298. KRISTENSEN KB, Thomsen IMN, Berg T, Kodahl AR, et al
    Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Apr 10. pii: 10.1007/s10549-021-06215.
    PubMed     Abstract available


  299. MCSORLEY LM, Tharmabala M, Al Rahbi F, McSorley K, et al
    Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland.
    Breast Cancer Res Treat. 2021 Apr 9. pii: 10.1007/s10549-021-06211.
    PubMed     Abstract available


  300. JOHNSON AE, Coopey SB, Spring LM, Horick NK, et al
    Management and outcomes of men diagnosed with primary breast cancer.
    Breast Cancer Res Treat. 2021 Apr 8. pii: 10.1007/s10549-021-06174.
    PubMed     Abstract available


  301. TURBOW SD, White MC, Breslau ES, Sabatino SA, et al
    Correction to: Mammography use and breast cancer incidence among older U.S. women.
    Breast Cancer Res Treat. 2021 Apr 5. pii: 10.1007/s10549-021-06212.
    PubMed    


  302. BATTISTI NML, Andres MS, Lee KA, Ramalingam S, et al
    Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer.
    Breast Cancer Res Treat. 2021 Apr 5. pii: 10.1007/s10549-021-06192.
    PubMed     Abstract available


  303. CHETRIT A, Ben-Avraham S, Mandelzweig L, Amitai T, et al
    Breast cancer survivors: physical and mental quality of life 10 years following diagnosis, a case-control study.
    Breast Cancer Res Treat. 2021 Apr 5. pii: 10.1007/s10549-021-06156.
    PubMed     Abstract available


  304. SUTTON AL, Felix AS, Bandyopadhyay D, Retnam R, et al
    Cardioprotective medication use in Black and white breast cancer survivors.
    Breast Cancer Res Treat. 2021 Apr 2. pii: 10.1007/s10549-021-06202.
    PubMed     Abstract available


  305. CHALASANI P, Farr K, Wu V, Jenkins I, et al
    Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Apr 2. pii: 10.1007/s10549-021-06175.
    PubMed     Abstract available


  306. PAWLOSKI KR, Tadros AB, Sevilimedu V, Newman A, et al
    Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy.
    Breast Cancer Res Treat. 2021;186:617-624.
    PubMed     Abstract available


  307. KOJIMAHARA T, Kageyama T
    Octopus anastomosis: selection of anastomotic configuration in lymphaticovenular anastomosis according to vessels' conditions.
    Breast Cancer Res Treat. 2021;186:887-888.
    PubMed    


  308. LANCETA L, Lypova N, O'Neill C, Li X, et al
    Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq.
    Breast Cancer Res Treat. 2021;186:677-686.
    PubMed     Abstract available


  309. JIAGGE EM, Ulintz PJ, Wong S, McDermott SP, et al
    Multiethnic PDX models predict a possible immune signature associated with TNBC of African ancestry.
    Breast Cancer Res Treat. 2021;186:391-401.
    PubMed     Abstract available


  310. PARKES A, Wang WL, Patel S, Leung CH, et al
    Outcomes of systemic therapy in metastatic phyllodes tumor of the breast.
    Breast Cancer Res Treat. 2021;186:871-882.
    PubMed     Abstract available


  311. GRILL S, Yahiaoui-Doktor M, Basrai M, Struck J, et al
    Precursor fractions of neurotensin and enkephalin might point to molecular mechanisms of cancer risk modulation during a lifestyle-intervention in germline BRCA1/2 gene mutation carriers.
    Breast Cancer Res Treat. 2021;186:741-752.
    PubMed     Abstract available


  312. YANG L, Roy M, Lin H, Shen Y, et al
    Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast.
    Breast Cancer Res Treat. 2021;186:403-415.
    PubMed     Abstract available


  313. ZHI WI, Baser RE, Kwon A, Chen C, et al
    Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing.
    Breast Cancer Res Treat. 2021;186:761-768.
    PubMed     Abstract available


  314. ALDOSARY G, Caudrelier JM, Arnaout A, Chang L, et al
    Can we rely on surgical clips placed during oncoplastic breast surgery to accurately delineate the tumor bed for targeted breast radiotherapy?
    Breast Cancer Res Treat. 2021;186:343-352.
    PubMed     Abstract available


  315. FILIPE MD, Patuleia SIS, Vriens MR, van Diest PJ, et al
    Meta-analysis and cost-effectiveness of ductoscopy, duct excision surgery and MRI for the diagnosis and treatment of patients with pathological nipple discharge.
    Breast Cancer Res Treat. 2021;186:285-293.
    PubMed     Abstract available


  316. GUI G, Panopoulou E, Tang S, Twelves D, et al
    The INTEND 1 randomized controlled trial of duct endoscopy as an indicator of margin excision in breast conservation surgery.
    Breast Cancer Res Treat. 2021;186:723-730.
    PubMed     Abstract available


  317. HUANG CS, Lu TP, Liu CY, Huang CJ, et al
    Residual risk stratification of Taiwanese breast cancers following curative therapies with the extended concurrent genes signature.
    Breast Cancer Res Treat. 2021;186:475-485.
    PubMed     Abstract available


  318. HA SM, Chang JM, Kim SY, Lee SH, et al
    Prediction of axillary nodal burden in patients with invasive lobular carcinoma using MRI.
    Breast Cancer Res Treat. 2021;186:463-473.
    PubMed     Abstract available


  319. KELLY BN, Kantor O, Tang R, Coopey SB, et al
    Similar rates of residual disease in patients with DCIS within 2 mm of lumpectomy margin regardless of the presence of invasive carcinoma.
    Breast Cancer Res Treat. 2021;186:807-814.
    PubMed     Abstract available


  320. HALASZ SR, O'Keefe T, Wallace AM, Blair SL, et al
    Ductal carcinoma in situ in patients younger than 30 years: differences in adjuvant endocrine therapy and outcomes.
    Breast Cancer Res Treat. 2021;186:551-559.
    PubMed     Abstract available


    March 2021
  321. HELBRICH H, Braun M, Hanusch C, Mueller G, et al
    Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer.
    Breast Cancer Res Treat. 2021 Mar 31. pii: 10.1007/s10549-021-06195.
    PubMed     Abstract available


  322. WANG YQ, Huang G, Chen J, Cao H, et al
    LncRNA SNHG6 promotes breast cancer progression and epithelial-mesenchymal transition via miR-543/LAMC1 axis.
    Breast Cancer Res Treat. 2021 Mar 29. pii: 10.1007/s10549-021-06190.
    PubMed     Abstract available


  323. NISHIKAWA S, Uemoto Y, Kim TS, Hisada T, et al
    Low RAI2 expression is a marker of poor prognosis in breast cancer.
    Breast Cancer Res Treat. 2021 Mar 29. pii: 10.1007/s10549-021-06176.
    PubMed     Abstract available


  324. AN KY, Arthuso FZ, Kang DW, Morielli AR, et al
    Exercise and health-related fitness predictors of chemotherapy completion in breast cancer patients: pooled analysis of two multicenter trials.
    Breast Cancer Res Treat. 2021 Mar 29. pii: 10.1007/s10549-021-06205.
    PubMed     Abstract available


  325. REINHORN D, Kuchuk I, Shochat T, Nisenbaum B, et al
    Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study.
    Breast Cancer Res Treat. 2021 Mar 27. pii: 10.1007/s10549-021-06198.
    PubMed     Abstract available


  326. LEONE J, Freedman RA, Lin NU, Tolaney SM, et al
    Tumor subtypes and survival in male breast cancer.
    Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06182.
    PubMed     Abstract available


  327. AHN SG, Kim SK, Shepherd JH, Cha YJ, et al
    Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
    Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06193.
    PubMed     Abstract available


  328. OPPONG BA, Obeng-Gyasi S, Relation T, Adams-Campbell L, et al
    Call to action: breast cancer screening recommendations for Black women.
    Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06207.
    PubMed     Abstract available


  329. CHEN I, Botty Van den Bruele AM, Gillespie EF, Mueller BA, et al
    Salvage of locally recurrent breast cancer with repeat breast conservation using 45 Gy hyperfractionated partial breast re-irradiation.
    Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06206.
    PubMed     Abstract available


  330. HO PJ, Dorajoo R, Ivankovic I, Ong SS, et al
    DNA methylation and breast cancer-associated variants.
    Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06185.
    PubMed     Abstract available


  331. MASUDA N, Bando H, Yamanaka T, Kadoya T, et al
    Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
    Breast Cancer Res Treat. 2021 Mar 25. pii: 10.1007/s10549-021-06184.
    PubMed     Abstract available


  332. WANG C, Tong F, Cao Y, Liu P, et al
    Long-term follow-up results of fluorescence and blue dye guided sentinel lymph node biopsy in early breast cancer.
    Breast Cancer Res Treat. 2021 Mar 24. pii: 10.1007/s10549-021-06196.
    PubMed     Abstract available


  333. MCGEE S, Alzahrani M, Vandermeer L, Cole K, et al
    Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey.
    Breast Cancer Res Treat. 2021 Mar 23. pii: 10.1007/s10549-021-06147.
    PubMed     Abstract available


  334. THOMAS S, Kabir M, Butcher BE, Chou S, et al
    Interobserver concordance in visual assessment of Ki67 immunohistochemistry in surgical excision specimens from patients with lymph node-negative breast cancer.
    Breast Cancer Res Treat. 2021 Mar 22. pii: 10.1007/s10549-021-06188.
    PubMed     Abstract available


  335. BUCKLEY E, Elder E, McGill S, Kargar ZS, et al
    Breast cancer treatment and survival differences in women in remote and socioeconomically disadvantaged areas, as demonstrated by linked data from New South Wales (NSW), Australia.
    Breast Cancer Res Treat. 2021 Mar 21. pii: 10.1007/s10549-021-06170.
    PubMed     Abstract available


  336. KUEMMEL S, Tondini CA, Abraham J, Nowecki Z, et al
    Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
    Breast Cancer Res Treat. 2021 Mar 21. pii: 10.1007/s10549-021-06145.
    PubMed     Abstract available


  337. IBRAGIMOVA KIE, Geurts SME, Croes S, Erdkamp F, et al
    Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.
    Breast Cancer Res Treat. 2021 Mar 20. pii: 10.1007/s10549-021-06178.
    PubMed     Abstract available


  338. GHARZAI LA, Szczygiel LA, Shumway DA, Bandos H, et al
    A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006).
    Breast Cancer Res Treat. 2021 Mar 19. pii: 10.1007/s10549-021-06172.
    PubMed     Abstract available


  339. WU ZY, Han HH, Kim HJ, Lee JW, et al
    A propensity score-matched comparison of recurrence outcomes after immediate implant vs autologous flap reconstruction in patients receiving neoadjuvant chemotherapy for breast cancer.
    Breast Cancer Res Treat. 2021 Mar 19. pii: 10.1007/s10549-021-06114.
    PubMed     Abstract available


  340. SHEEAN P, Matthews L, Visotcky A, Banerjee A, et al
    Every Day Counts: a randomized pilot lifestyle intervention for women with metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Mar 19. pii: 10.1007/s10549-021-06163.
    PubMed     Abstract available


  341. LLOYD KE, Hall LH, Ziegler L, Smith SG, et al
    Breast cancer worry in higher-risk women offered preventive therapy: a UK multicentre prospective study.
    Breast Cancer Res Treat. 2021 Mar 17. pii: 10.1007/s10549-021-06183.
    PubMed     Abstract available


  342. TOKUDA Y, Yanagawa M, Fujita Y, Honma K, et al
    Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer: comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanced MRI.
    Breast Cancer Res Treat. 2021 Mar 17. pii: 10.1007/s10549-021-06179.
    PubMed     Abstract available


  343. IM YH, Karabulut B, Lee KS, Park BW, et al
    Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
    Breast Cancer Res Treat. 2021 Mar 16. pii: 10.1007/s10549-021-06173.
    PubMed     Abstract available


  344. SURETTE A, Yoo BH, Younis T, Matheson K, et al
    Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies.
    Breast Cancer Res Treat. 2021 Mar 16. pii: 10.1007/s10549-021-06164.
    PubMed     Abstract available


  345. HETTERICH M, Gerken M, Ortmann O, Inwald EC, et al
    Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases.
    Breast Cancer Res Treat. 2021 Mar 15. pii: 10.1007/s10549-021-06162.
    PubMed     Abstract available


  346. WALSTRA CJEF, Schipper RJ, van Riet YE, van der Toorn PG, et al
    Repeat breast-conserving treatment of ipsilateral breast cancer recurrence: a nationwide survey amongst breast surgeons and radiation oncologists in the Netherlands.
    Breast Cancer Res Treat. 2021 Mar 13. pii: 10.1007/s10549-021-06154.
    PubMed     Abstract available


  347. FALTINOVA M, Vehmanen L, Lyytinen H, Haanpaa M, et al
    Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial.
    Breast Cancer Res Treat. 2021 Mar 12. pii: 10.1007/s10549-021-06168.
    PubMed     Abstract available


  348. LI XM, Chen HL
    RE: Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early stage breast cancer patients.
    Breast Cancer Res Treat. 2021 Mar 11. pii: 10.1007/s10549-021-06146.
    PubMed    


  349. FEI F, Siegal GP, Wei S
    Characterization of estrogen receptor-low-positive breast cancer.
    Breast Cancer Res Treat. 2021 Mar 10. pii: 10.1007/s10549-021-06148.
    PubMed     Abstract available


  350. MOOSSDORFF M, Vane MLG, van Nijnatten TJA, van Maaren MC, et al
    Conditional local recurrence risk: the effect of event-free years in different subtypes of breast cancer.
    Breast Cancer Res Treat. 2021 Mar 10. pii: 10.1007/s10549-020-06040.
    PubMed     Abstract available


  351. DANKWA-MULLAN I, George J, Roebuck MC, Tkacz J, et al
    Variations in breast cancer surgical treatment and timing: determinants and disparities.
    Breast Cancer Res Treat. 2021 Mar 10. pii: 10.1007/s10549-021-06155.
    PubMed     Abstract available


  352. PRADA D, Baccarelli AA, Terry MB, Valdez L, et al
    Long-term PM2.5 exposure before diagnosis is associated with worse outcome in breast cancer.
    Breast Cancer Res Treat. 2021 Mar 8. pii: 10.1007/s10549-021-06167.
    PubMed     Abstract available


  353. CHAWLA S, Hill A, Fearfield L, Johnston S, et al
    Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience.
    Breast Cancer Res Treat. 2021 Mar 8. pii: 10.1007/s10549-021-06169.
    PubMed     Abstract available


  354. LUO J, Kroenke CH, Hendryx M, Shadyab AH, et al
    Mediation analysis of racial disparities in triple-negative breast cancer incidence among postmenopausal women.
    Breast Cancer Res Treat. 2021 Mar 7. pii: 10.1007/s10549-021-06158.
    PubMed     Abstract available


  355. FALCONE M, Liu L, Farias A, Zhang J, et al
    Evidence for racial/ethnic disparities in emergency department visits following breast cancer surgery among women in California: a population-based study.
    Breast Cancer Res Treat. 2021 Mar 6. pii: 10.1007/s10549-021-06119.
    PubMed     Abstract available


  356. NGUYEN T, Irwin ML, Dewan AT, Cartmel B, et al
    Examining the effect of obesity-associated gene variants on breast cancer survivors in a randomized weight loss intervention.
    Breast Cancer Res Treat. 2021 Mar 6. pii: 10.1007/s10549-021-06151.
    PubMed     Abstract available


  357. TURBOW SD, White MC, Breslau ES, Sabatino SA, et al
    Mammography use and breast cancer incidence among older U.S. women.
    Breast Cancer Res Treat. 2021 Mar 5. pii: 10.1007/s10549-021-06160.
    PubMed     Abstract available


  358. ZDRAVKOVIC D, Petricevic S, Toskovic B
    Influence of different response after neoadjuvant chemotherapy on time of surgery in breast cancer patients.
    Breast Cancer Res Treat. 2021 Mar 4. pii: 10.1007/s10549-021-06161.
    PubMed    


  359. STRELL C, Stenmark Tullberg A, Jetne Edelmann R, Akslen LA, et al
    Prognostic and predictive impact of stroma cells defined by PDGFRb expression in early breast cancer: results from the randomized SweBCG91RT trial.
    Breast Cancer Res Treat. 2021 Mar 4. pii: 10.1007/s10549-021-06136.
    PubMed     Abstract available


  360. SMITH SG, Sestak I, Morris MA, Harvie M, et al
    The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies.
    Breast Cancer Res Treat. 2021 Mar 3. pii: 10.1007/s10549-021-06141.
    PubMed     Abstract available


  361. PARK KU, Gregory M, Bazan J, Lustberg M, et al
    Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic.
    Breast Cancer Res Treat. 2021 Mar 2. pii: 10.1007/s10549-021-06153.
    PubMed     Abstract available


  362. O'SHAUGHNESSY J, Robert N, Annavarapu S, Zhou J, et al
    Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study.
    Breast Cancer Res Treat. 2021 Mar 1. pii: 10.1007/s10549-021-06137.
    PubMed     Abstract available


  363. IACUZZO C, Giudici F, Scomersi S, Ceccherini R, et al
    Direct comparison of three different mathematical models in two independent datasets of EUSOMA certified centers to predict recurrence and survival in estrogen receptor-positive breast cancer: impact on clinical practice.
    Breast Cancer Res Treat. 2021 Mar 1. pii: 10.1007/s10549-021-06144.
    PubMed     Abstract available


    February 2021
  364. KAUFMAN PA, Hurvitz SA, O'Shaughnessy J, Mason G, et al
    Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.
    Breast Cancer Res Treat. 2021 Feb 28. pii: 10.1007/s10549-021-06103.
    PubMed     Abstract available


  365. SUELMANN BBM, van Dooijeweert C, van der Wall E, Linn S, et al
    Pregnancy-associated breast cancer: nationwide Dutch study confirms a discriminatory aggressive histopathologic profile.
    Breast Cancer Res Treat. 2021 Feb 26. pii: 10.1007/s10549-021-06130.
    PubMed     Abstract available


  366. TARANTINO P, Curigliano G
    Activity of novel anti-HER2 agents for breast cancer based on hormone receptors expression.
    Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06150.
    PubMed    


  367. LIU J, Li Y, Li Q, Liang D, et al
    Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients.
    Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06128.
    PubMed     Abstract available


  368. WANG YF, Wang XJ, Lu Z, Liu SR, et al
    Overexpression of Stat3 increases circulating cfDNA in breast cancer.
    Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06142.
    PubMed     Abstract available


  369. WARE AW, Harris JJ, Slatter TL, Cunliffe HE, et al
    The epithelial sodium channel has a role in breast cancer cell proliferation.
    Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06133.
    PubMed     Abstract available


  370. BRUNELLE CL, Barrio AV, Taghian AG
    Letter to editor re: Shah et al.: "The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements".
    Breast Cancer Res Treat. 2021 Feb 25. pii: 10.1007/s10549-021-06139.
    PubMed    


  371. CHANDRIKA M, Chua PJ, Muniasamy U, Huang RYJ, et al
    Prognostic significance of phosphoglycerate dehydrogenase in breast cancer.
    Breast Cancer Res Treat. 2021 Feb 24. pii: 10.1007/s10549-021-06123.
    PubMed     Abstract available


  372. PRUITT SL, Zhu H, Heitjan DF, Rahimi A, et al
    Survival of women diagnosed with breast cancer and who have survived a previous cancer.
    Breast Cancer Res Treat. 2021 Feb 23. pii: 10.1007/s10549-021-06122.
    PubMed     Abstract available


  373. VALLA M, Opdahl S, Ytterhus B, Bofin AM, et al
    DTX3 copy number increase in breast cancer: a study of associations to molecular subtype, proliferation and prognosis.
    Breast Cancer Res Treat. 2021 Feb 22. pii: 10.1007/s10549-021-06138.
    PubMed     Abstract available


  374. TANG M, Schaffer AL, Kiely BE, Daniels B, et al
    Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study.
    Breast Cancer Res Treat. 2021 Feb 22. pii: 10.1007/s10549-021-06135.
    PubMed     Abstract available


  375. GUHA R, Yue B, Dong J, Banerjee A, et al
    Anti-progranulin/GP88 antibody AG01 inhibits triple negative breast cancer cell proliferation and migration.
    Breast Cancer Res Treat. 2021 Feb 22. pii: 10.1007/s10549-021-06120.
    PubMed     Abstract available


  376. DUARTE C, Salazar A, Strasser-Weippl K, de Vries E, et al
    Breast cancer in Colombia: a growing challenge for the healthcare system.
    Breast Cancer Res Treat. 2021 Feb 21. pii: 10.1007/s10549-020-06091.
    PubMed     Abstract available


  377. MAN V, Kwong A
    Different strategies in marking axillary lymph nodes in breast cancer patients undergoing neoadjuvant medical treatment: a systematic review.
    Breast Cancer Res Treat. 2021 Feb 21. pii: 10.1007/s10549-021-06118.
    PubMed     Abstract available


  378. LANAHAN CR, Kelly BN, Gadd MA, Specht MC, et al
    Performance of a novel protease-activated fluorescent imaging system for intraoperative detection of residual breast cancer during breast conserving surgery.
    Breast Cancer Res Treat. 2021 Feb 21. pii: 10.1007/s10549-021-06106.
    PubMed     Abstract available


  379. TESCH ME, Chia SK, Simmons CE, LeVasseur N, et al
    Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients.
    Breast Cancer Res Treat. 2021 Feb 20. pii: 10.1007/s10549-021-06110.
    PubMed     Abstract available


  380. JOHNSON HM, Irish W, Vohra NA, Wong JH, et al
    Refining breast cancer prognosis by incorporating age at diagnosis into clinical prognostic staging: introduction of a novel online calculator.
    Breast Cancer Res Treat. 2021 Feb 20. pii: 10.1007/s10549-021-06113.
    PubMed     Abstract available


  381. RITTER M, Ling BM, Oberhauser I, Montagna G, et al
    The impact of age on patient-reported outcomes after oncoplastic versus conventional breast cancer surgery.
    Breast Cancer Res Treat. 2021 Feb 19. pii: 10.1007/s10549-021-06126.
    PubMed     Abstract available


  382. CHEN QX, Yang YZ, Liang ZZ, Chen JL, et al
    Time-varying effects of FOXA1 on breast cancer prognosis.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06125.
    PubMed     Abstract available


  383. KIM J, Hong S, Lee JJ, Won YJ, et al
    Analysis of the tumor characteristics in young age breast cancer patients using collaborative stage data of the Korea Central Cancer Registry.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06107.
    PubMed     Abstract available


  384. ALBINSAAD LS, Kim J, Chung IY, Ko BS, et al
    Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06134.
    PubMed     Abstract available


  385. KIM KH, Choi S, Kim K, Chang J, et al
    Association between physical activity and subsequent cardiovascular disease among 5-year breast cancer survivors.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06140.
    PubMed     Abstract available


  386. CAO S, Zhu Z, Zhou J, Li W, et al
    Associations of one-carbon metabolism-related gene polymorphisms with breast cancer risk are modulated by diet, being higher when adherence to the Mediterranean dietary pattern is low.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06108.
    PubMed     Abstract available


  387. GEBREMARIAM A, Assefa M, Addissie A, Worku A, et al
    Delayed initiation of adjuvant chemotherapy among women with breast cancer in Addis Ababa, Ethiopia.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06131.
    PubMed     Abstract available


  388. MINK VAN DER MOLEN DR, Bargon CA, Batenburg MCT, Gal R, et al
    (Ex-)breast cancer patients with (pre-existing) symptoms of anxiety and/or depression experience higher barriers to contact health care providers during the COVID-19 pandemic.
    Breast Cancer Res Treat. 2021 Feb 18. pii: 10.1007/s10549-021-06112.
    PubMed     Abstract available


  389. WANG Y, Singh K, Dizon D, Graves T, et al
    Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer.
    Breast Cancer Res Treat. 2021 Feb 17. pii: 10.1007/s10549-021-06124.
    PubMed     Abstract available


  390. JALLOUK AP, Paravastu S, Weilbaecher K, Aft RL, et al
    Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer.
    Breast Cancer Res Treat. 2021 Feb 16. pii: 10.1007/s10549-021-06100.
    PubMed     Abstract available


  391. WARDLEY A, Cortes J, Provencher L, Miller K, et al
    The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
    Breast Cancer Res Treat. 2021 Feb 16. pii: 10.1007/s10549-021-06109.
    PubMed     Abstract available


  392. LEONE JP, Leone BA, Tayob N, Hassett MJ, et al
    Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry.
    Breast Cancer Res Treat. 2021 Feb 16. pii: 10.1007/s10549-021-06121.
    PubMed     Abstract available


  393. NGUY S, Wu SP, Oh C, Gerber NK, et al
    Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy.
    Breast Cancer Res Treat. 2021 Feb 15. pii: 10.1007/s10549-021-06115.
    PubMed     Abstract available


  394. LIZARRAGA IM, Kahl AR, Jacoby E, Charlton ME, et al
    Impact of age, rurality and distance in predicting contralateral prophylactic mastectomy for breast cancer in a Midwestern state: a population-based study.
    Breast Cancer Res Treat. 2021 Feb 13. pii: 10.1007/s10549-021-06105.
    PubMed     Abstract available


  395. PEATE M, Saunders C, Cohen P, Hickey M, et al
    Who is managing menopausal symptoms, sexual problems, mood and sleep disturbance after breast cancer and is it working? Findings from a large community-based survey of breast cancer survivors.
    Breast Cancer Res Treat. 2021 Feb 11. pii: 10.1007/s10549-021-06117.
    PubMed     Abstract available


  396. LIU M, Xie F, Liu M, Zhang Y, et al
    Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2021 Feb 9. pii: 10.1007/s10549-021-06104.
    PubMed     Abstract available


  397. COLETTA AM, Agha NH, Baker FL, Niemiro GM, et al
    The impact of high-intensity interval exercise training on NK-cell function and circulating myokines for breast cancer prevention among women at high risk for breast cancer.
    Breast Cancer Res Treat. 2021 Feb 8. pii: 10.1007/s10549-021-06111.
    PubMed     Abstract available


  398. DA SILVA LR, de Andrade CA, Brenelli F, Ramalho S, et al
    Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer.
    Breast Cancer Res Treat. 2021 Feb 4. pii: 10.1007/s10549-020-06076.
    PubMed     Abstract available


  399. RAFN BS, Christensen J, Bloomquist K
    Letter to the editor re: Shah et al.: "The impact of monitoring techniques on progression to chronic breast cancerrelated lymphedema: a metaanalysis comparing bioimpedance spectroscopy versus circumferential measurements".
    Breast Cancer Res Treat. 2021;186:269-270.
    PubMed    


  400. YANG C, Arnold AG, Catchings A, Rai V, et al
    The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer.
    Breast Cancer Res Treat. 2021;185:869-877.
    PubMed     Abstract available


  401. SHANI H, Bernstein-Molho R, Laitman Y, Netzer I, et al
    Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations.
    Breast Cancer Res Treat. 2021;186:259-263.
    PubMed     Abstract available


  402. SCHUMACHER K, Inciardi M, O'Neil M, Wagner JL, et al
    Is axillary imaging for invasive lobular carcinoma accurate in determining clinical node staging?
    Breast Cancer Res Treat. 2021;185:567-572.
    PubMed     Abstract available


  403. WU JM, Galibois AA, Seebocus N, Apu A, et al
    HER2 fluorescent in situ hybridization signal degradation: a 10-year retrospective study.
    Breast Cancer Res Treat. 2021;186:99-105.
    PubMed     Abstract available


  404. ZHANG Z, Chen X, Zhang J, Dai X, et al
    Cancer stem cell transcriptome landscape reveals biomarkers driving breast carcinoma heterogeneity.
    Breast Cancer Res Treat. 2021;186:89-98.
    PubMed     Abstract available


  405. OHNO S, Saji S, Masuda N, Tsuda H, et al
    Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur-uracil with CMF (N.SAS-BC 01 trial and CUBC trial).
    Breast Cancer Res Treat. 2021;186:135-147.
    PubMed     Abstract available


  406. KOPANS DB
    The wisdom trial is based on faulty reasoning and has major design and execution problems.
    Breast Cancer Res Treat. 2021;185:549-556.
    PubMed     Abstract available


  407. PARKS RM, Albanghali MA, Syed BM, Green AR, et al
    Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray.
    Breast Cancer Res Treat. 2021;185:647-655.
    PubMed     Abstract available


  408. MESSORI A, Bartoli L, Ferracane E
    Implant-based breast reconstruction: re-analysis of the odds ratio for skin flap necrosis.
    Breast Cancer Res Treat. 2021;185:887.
    PubMed    


  409. LACOUTURE ME, Dion H, Ravipaty S, Jimenez JJ, et al
    A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia.
    Breast Cancer Res Treat. 2021;186:107-114.
    PubMed     Abstract available


  410. NARAYAN AK, Mercaldo SF, Gupta YP, Warner ET, et al
    Potential of using mammography screening appointments to identify high-risk women: cross sectional survey results from the national health interview survey.
    Breast Cancer Res Treat. 2021;186:229-235.
    PubMed     Abstract available


  411. RABAGLIO M, Sun Z, Maibach R, Giobbie-Hurder A, et al
    Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
    Breast Cancer Res Treat. 2021;185:697-707.
    PubMed     Abstract available


  412. RASCHI E, Fusaroli M, Ardizzoni A, Poluzzi E, et al
    Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
    Breast Cancer Res Treat. 2021;186:219-227.
    PubMed     Abstract available


  413. TARANTINO P, Prat A, Curigliano G
    New anti-HER2 agents for brain metastasis: histology-agnostic weapons?
    Breast Cancer Res Treat. 2021;185:879-881.
    PubMed     Abstract available


  414. GOMES R, Spinola PDS, Brant AC, Matta BP, et al
    Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.
    Breast Cancer Res Treat. 2021;185:851-861.
    PubMed     Abstract available


  415. ALIPOUR S
    Re: Naoum et al., Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy.
    Breast Cancer Res Treat. 2021;185:885-886.
    PubMed    


  416. RAPHAEL DANIELA DB, Russell NS, van Werkhoven E, Immink JM, et al
    Implementing a patient decision aid, a process evaluation of a large-scale pre- and post-implementation trial.
    Breast Cancer Res Treat. 2021;185:685-695.
    PubMed     Abstract available


  417. LI X, Ma Z, Styblo TM, Arciero CA, et al
    Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high-risk breast lesion conferences at an academic institution.
    Breast Cancer Res Treat. 2021;185:573-581.
    PubMed     Abstract available


  418. LLANOS AAM, Yao S, Singh A, Aremu JB, et al
    Gene expression of adipokines and adipokine receptors in the tumor microenvironment: associations of lower expression with more aggressive breast tumor features.
    Breast Cancer Res Treat. 2021;185:785-798.
    PubMed     Abstract available


    January 2021
  419. YAO KA, Attai D, Bleicher R, Kuchta K, et al
    Covid-19 related oncologist's concerns about breast cancer treatment delays and physician well-being (the CROWN study).
    Breast Cancer Res Treat. 2021 Jan 31. pii: 10.1007/s10549-021-06101.
    PubMed     Abstract available


  420. SHARMA R
    Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018.
    Breast Cancer Res Treat. 2021 Jan 30. pii: 10.1007/s10549-020-06083.
    PubMed     Abstract available


  421. VAN DOOIJEWEERT C, Baas IO, Deckers IAG, Siesling S, et al
    The increasing importance of histologic grading in tailoring adjuvant systemic therapy in 30,843 breast cancer patients.
    Breast Cancer Res Treat. 2021 Jan 30. pii: 10.1007/s10549-021-06098.
    PubMed     Abstract available


  422. SUKUMAR J, Kassem M, Agnese D, Pilarski R, et al
    Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series.
    Breast Cancer Res Treat. 2021 Jan 28. pii: 10.1007/s10549-021-06095.
    PubMed     Abstract available


  423. ZHAO H, Song R, Ye Y, Chow WH, et al
    Allostatic score and its associations with demographics, healthy behaviors, tumor characteristics, and mitochondrial DNA among breast cancer patients.
    Breast Cancer Res Treat. 2021 Jan 28. pii: 10.1007/s10549-021-06102.
    PubMed     Abstract available


  424. KELLY KN, Hernandez A, Yadegarynia S, Ryon E, et al
    Overcoming disparities: Multidisciplinary breast cancer care at a public safety net hospital.
    Breast Cancer Res Treat. 2021 Jan 25. pii: 10.1007/s10549-020-06044.
    PubMed     Abstract available


  425. WEBBER C, Whitehead M, Eisen A, Holloway CMB, et al
    Factors associated with waiting time to breast cancer diagnosis among symptomatic breast cancer patients: a population-based study from Ontario, Canada.
    Breast Cancer Res Treat. 2021 Jan 24. pii: 10.1007/s10549-020-06051.
    PubMed     Abstract available


  426. SUEOKA S, Sasada S, Masumoto N, Emi A, et al
    Performance of dedicated breast positron emission tomography in the detection of small and low-grade breast cancer.
    Breast Cancer Res Treat. 2021 Jan 23. pii: 10.1007/s10549-020-06088.
    PubMed     Abstract available


  427. DODINGTON DW, Lagree A, Tabbarah S, Mohebpour M, et al
    Analysis of tumor nuclear features using artificial intelligence to predict response to neoadjuvant chemotherapy in high-risk breast cancer patients.
    Breast Cancer Res Treat. 2021 Jan 23. pii: 10.1007/s10549-020-06093.
    PubMed     Abstract available


  428. JAFARI L, Akhter N
    Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review.
    Breast Cancer Res Treat. 2021 Jan 22. pii: 10.1007/s10549-021-06096.
    PubMed     Abstract available


  429. AL-MASRI M, Aljalabneh B, Al-Najjar H, Al-Shamaileh T, et al
    Effect of time to breast cancer surgery after neoadjuvant chemotherapy on survival outcomes.
    Breast Cancer Res Treat. 2021 Jan 21. pii: 10.1007/s10549-020-06090.
    PubMed     Abstract available


  430. IWASE T, Wang X, Shrimanker TV, Kolonin MG, et al
    Body composition and breast cancer risk and treatment: mechanisms and impact.
    Breast Cancer Res Treat. 2021 Jan 21. pii: 10.1007/s10549-020-06092.
    PubMed     Abstract available


  431. MONDACA JM, Guijarro ACC, Flamini MI, Sanchez AM, et al
    Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+ breast cancer.
    Breast Cancer Res Treat. 2021 Jan 20. pii: 10.1007/s10549-020-06089.
    PubMed     Abstract available


  432. SHECKTER CC, Aliu O, Bailey C, Liu J, et al
    Exploring provider- and practice-level drivers of cost-consciousness in breast cancer reconstruction-secondary analysis of a survey of the American Society of Plastic Surgeons.
    Breast Cancer Res Treat. 2021 Jan 19. pii: 10.1007/s10549-020-06085.
    PubMed     Abstract available


  433. KARADSHEH MJ, Tyrell R, Deng M, Egleston BL, et al
    Early postoperative outcomes in implant, pedicled, and free flap reconstruction for breast cancer: an analysis of 23,834 patients from the ACS-NSQIP datasets.
    Breast Cancer Res Treat. 2021 Jan 19. pii: 10.1007/s10549-020-06073.
    PubMed     Abstract available


  434. NAKASHOJI A, Hayashida T, Yamaguchi S, Kawai Y, et al
    Comprehensive analysis of the homeobox family genes in breast cancer demonstrates their similar roles in cancer and development.
    Breast Cancer Res Treat. 2021 Jan 18. pii: 10.1007/s10549-020-06087.
    PubMed     Abstract available


  435. COOLBRANDT A, T'Jonck A, Blauwens K, Dejaeger E, et al
    Scalp cooling in breast cancer patients treated with docetaxel-cyclophosphamide: patient- and nurse-reported results.
    Breast Cancer Res Treat. 2021 Jan 16. pii: 10.1007/s10549-020-06063.
    PubMed     Abstract available


  436. OBA T, Ono M, Matoba H, Uehara T, et al
    HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2021 Jan 16. pii: 10.1007/s10549-020-06033.
    PubMed     Abstract available


  437. APTECAR L, Fiteni F, Jarlier M, Delaine S, et al
    Prospective evaluation of sexual health in breast cancer women during the first year of adjuvant hormonal treatment using a cancer patient's dedicated questionnaire: A glaring gap of communication between health professionals and patients.
    Breast Cancer Res Treat. 2021 Jan 15. pii: 10.1007/s10549-020-06062.
    PubMed     Abstract available


  438. QI P, Yang Y, Bai QM, Xue T, et al
    Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients.
    Breast Cancer Res Treat. 2021 Jan 13. pii: 10.1007/s10549-020-06075.
    PubMed     Abstract available


  439. RICHARDSON D, Zhan L, Mahtani R, McRoy L, et al
    A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application.
    Breast Cancer Res Treat. 2021 Jan 11. pii: 10.1007/s10549-020-06082.
    PubMed     Abstract available


  440. STJEPANOVIC N, Lubinski J, Moller P, Randall Armel S, et al
    Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2021 Jan 10. pii: 10.1007/s10549-020-06072.
    PubMed     Abstract available


  441. ALEIXO GFP, Yu H, Chen YT, Nyrop KA, et al
    Myosteatosis evaluation using erector spinae and psoas muscles to predict adverse events during adjuvant chemotherapy for breast cancer.
    Breast Cancer Res Treat. 2021 Jan 10. pii: 10.1007/s10549-020-06061.
    PubMed     Abstract available


  442. WEI M, Wang X, Zimmerman DN, Burt LM, et al
    Endocrine therapy and radiotherapy use among older women with hormone receptor-positive, clinically node-negative breast cancer.
    Breast Cancer Res Treat. 2021 Jan 9. pii: 10.1007/s10549-020-06071.
    PubMed     Abstract available


  443. ZHANG J, Liu Y, Pu S, He J, et al
    Spindle and kinetochoreassociated complex subunit 3 accelerates breast cancer cell proliferation and invasion through the regulation of Akt/Wnt/beta-catenin signaling.
    Breast Cancer Res Treat. 2021 Jan 9. pii: 10.1007/s10549-020-06078.
    PubMed     Abstract available


  444. SOARES ICS, Bello MA, Bergmann A, Thuler LCS, et al
    Comparison of the performance of four staging systems in determining the prognosis of breast cancer among women undergoing neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2021 Jan 8. pii: 10.1007/s10549-020-06077.
    PubMed     Abstract available


  445. KUMAR U, Ardasheva A, Mahmud Z, Coombes RC, et al
    FOXA1 is a determinant of drug resistance in breast cancer cells.
    Breast Cancer Res Treat. 2021 Jan 8. pii: 10.1007/s10549-020-06068.
    PubMed     Abstract available


  446. DI MICCO R, Classe JM, Reimer T
    Letter to the Editor regarding the publication titled "Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?"
    Breast Cancer Res Treat. 2021 Jan 7. pii: 10.1007/s10549-020-06064.
    PubMed    


  447. VAN MECHELEN M, Van Herck A, Punie K, Nevelsteen I, et al
    Correction to: Behavior of metastatic breast cancer according to subtype.
    Breast Cancer Res Treat. 2021 Jan 7. pii: 10.1007/s10549-020-06006.
    PubMed    


  448. KHOURY K, Lynce F, Barac A, Geng X, et al
    Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.
    Breast Cancer Res Treat. 2021 Jan 5. pii: 10.1007/s10549-020-06053.
    PubMed     Abstract available


  449. KONISHI T, Fujiogi M, Michihata N, Morita K, et al
    Comparison of short-term surgical outcomes between men and women with breast cancer: a retrospective study using nationwide inpatient data in Japan.
    Breast Cancer Res Treat. 2021 Jan 5. pii: 10.1007/s10549-020-06069.
    PubMed     Abstract available


  450. MACKEY JR, Lai J, Chauhan U, Beauchamp E, et al
    N-myristoyltransferase proteins in breast cancer: prognostic relevance and validation as a new drug target.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06037.
    PubMed     Abstract available


  451. GAUDET MM, Deubler E, Diver WR, Puvanesarajah S, et al
    Breast cancer risk factors by mode of detection among screened women in the Cancer Prevention Study-II.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06025.
    PubMed     Abstract available


  452. BOUWER NI, Steenbruggen TG, van Rosmalen J, Rier HN, et al
    Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06039.
    PubMed     Abstract available


  453. KIM JS, Kim K, Jung W, Shin KH, et al
    New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12).
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06043.
    PubMed     Abstract available


  454. KLEINSTERN G, Scott CG, Tamimi RM, Jensen MR, et al
    Association of mammographic density measures and breast cancer "intrinsic" molecular subtypes.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06049.
    PubMed     Abstract available


  455. WILLIAMS AM, Khan CP, Heckler CE, Barton DL, et al
    Fatigue, anxiety, and quality of life in breast cancer patients compared to non-cancer controls: a nationwide longitudinal analysis.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06067.
    PubMed     Abstract available


  456. RAJAGOPAL T, Seshachalam A, Rathnam KK, Jothi A, et al
    Impact of xenobiotic-metabolizing gene polymorphisms on breast cancer risk in South Indian women.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06028.
    PubMed     Abstract available


  457. SUTHERLAND A, Wagner JL, Korentager S, Butterworth J, et al
    Is bioimpedance spectroscopy a useful tool for objectively assessing lymphovenous bypass surgical outcomes in breast cancer-related lymphedema?
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06059.
    PubMed     Abstract available


  458. ZEIDMAN M, Schmidt H, Alberty-Oller JJ, Pisapati KV, et al
    Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB).
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06041.
    PubMed     Abstract available


  459. MORAVEK MB, Confino R, Lawson AK, Smith KN, et al
    Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06031.
    PubMed     Abstract available


  460. LI Z, Wang Y, Liu C, Wang Z, et al
    Association between VEGF single nucleotide polymorphism and breast cancer in the Northern China Han population.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06024.
    PubMed     Abstract available


  461. GOETZ MP, Okera M, Wildiers H, Campone M, et al
    Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06029.
    PubMed     Abstract available


  462. STENEHJEM DD, Telford C, Unni SK, Bauer H, et al
    BRCA testing and outcomes in women with breast cancer.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06038.
    PubMed     Abstract available


  463. POLLEY MC, Leon-Ferre RA, Leung S, Cheng A, et al
    A clinical calculator to predict disease outcomes in women with triple-negative breast cancer.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06030.
    PubMed     Abstract available


  464. JONES S, Hogan B, Patel K, Ooi S, et al
    Identification of factors that influence the decision to take chemoprevention in patients with a significant family history of breast cancer: results from a patient questionnaire survey.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06046.
    PubMed     Abstract available


  465. KENNARD K, Buckley ME, Sizer LM, Larson S, et al
    Metabolic Syndrome: does this influence breast cancer outcomes in the triple-negative population?
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06034.
    PubMed     Abstract available


  466. LUANGWATTANANUN P, Junking M, Sujjitjoon J, Wutti-In Y, et al
    Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06032.
    PubMed     Abstract available


  467. KANG YJ, Oh SJ, Choi H, Cho S, et al
    Clinical significance of HER2 status in T1bN0 breast cancer: a nationwide study from the Korean Breast Cancer Society.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06017.
    PubMed     Abstract available


  468. TZEKAKI EE, Geromichalos G, Lavrentiadou SN, Tsantarliotou MP, et al
    Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06054.
    PubMed     Abstract available


  469. SHLIAKHTUNOU YA
    CTCs-oriented adjuvant personalized cytostatic therapy non-metastatic breast cancer patients: continuous non-randomized prospective study and prospective randomized controlled study.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06036.
    PubMed     Abstract available


  470. LEONE JP, Leone BA, Zwenger AO, Vallejo CT, et al
    The prognostic significance of metastatic pattern in stage IV male breast cancer at initial diagnosis: a population-based study.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06052.
    PubMed     Abstract available


  471. KLAESTAD E, Sawicka JE, Engstrom MJ, Ytterhus B, et al
    ZNF703 gene copy number and protein expression in breast cancer; associations with proliferation, prognosis and luminal subtypes.
    Breast Cancer Res Treat. 2021 Jan 2. pii: 10.1007/s10549-020-06035.
    PubMed     Abstract available


  472. VILLARREAL-GARZA C, Mesa-Chavez F, Garza-Ledezma MRA, Pena-Curiel O, et al
    Impact of chemotherapy regimen and sequence on the effectiveness of scalp cooling for alopecia prevention.
    Breast Cancer Res Treat. 2021;185:453-458.
    PubMed     Abstract available


  473. COX K, Dineen N, Taylor-Phillips S, Sharma N, et al
    Enhanced axillary assessment using intradermally injected microbubbles and contrast-enhanced ultrasound (CEUS) before neoadjuvant systemic therapy (NACT) identifies axillary disease missed by conventional B-mode ultrasound that may be clinically relev
    Breast Cancer Res Treat. 2021;185:413-422.
    PubMed     Abstract available


  474. SADEGHALVAD M, Mohammadi-Motlagh HR, Rezaei N
    Immune microenvironment in different molecular subtypes of ductal breast carcinoma.
    Breast Cancer Res Treat. 2021;185:261-279.
    PubMed     Abstract available


  475. POLAT DS, Schopp JG, Arjmandi F, Porembka J, et al
    Performance of a clinical and imaging-based multivariate model as decision support tool to help save unnecessary surgeries for high-risk breast lesions.
    Breast Cancer Res Treat. 2021;185:479-494.
    PubMed     Abstract available


  476. APPELMAN L, Appelman PTM, Siebers CCN, Bult P, et al
    The value of mammography in women with focal breast complaints in addition to initial targeted ultrasound.
    Breast Cancer Res Treat. 2021;185:381-389.
    PubMed     Abstract available


  477. GALMOR L, Bernstein-Molho R, Sklair-Levy M, Madoursky-Feldman D, et al
    Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2021;185:391-399.
    PubMed     Abstract available


  478. MANNLE H, Siebers JW, Momm F, Munstedt K, et al
    Impact of patients' refusal to undergo adjuvant treatment measures on survival.
    Breast Cancer Res Treat. 2021;185:239-246.
    PubMed     Abstract available


  479. PONDE N, Agbor-Tarh D, Dal Lago L, Korde LA, et al
    Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).
    Breast Cancer Res Treat. 2021;185:107-116.
    PubMed     Abstract available


  480. DENG J, Thennavan A, Shah S, Bagdatlioglu E, et al
    Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment.
    Breast Cancer Res Treat. 2021;185:85-94.
    PubMed     Abstract available


  481. TOUSSAINT A, Piaget-Rossel R, Stormacq C, Mathevet P, et al
    Width of margins in phyllodes tumors of the breast: the controversy drags on?-a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2021;185:21-37.
    PubMed     Abstract available


  482. BAEK SY, Kim J, Chung IY, Ko BS, et al
    Long-term survival outcomes of repeat lumpectomy for ipsilateral breast tumor recurrence: a propensity score-matched analysis.
    Breast Cancer Res Treat. 2021;185:155-164.
    PubMed     Abstract available


  483. SOMASUNDARAM SK, Potter S, Elgammal S, Maxwell AJ, et al
    Impalpable breast lesion localisation, a logistical challenge: results of the UK iBRA-NET national practice questionnaire.
    Breast Cancer Res Treat. 2021;185:13-20.
    PubMed     Abstract available


    December 2020
  484. ALTUNDAG K
    Luminal subtypes and response to neoadjuvant chemotherapy for hormone receptor-positive HER2-negative patients.
    Breast Cancer Res Treat. 2020;184:999.
    PubMed    


    November 2020
  485. SCHIZA A, Mauri D, Fredriksson I, Anna-Karin Wennstig, et al
    Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study.
    Breast Cancer Res Treat. 2020 Nov 30. pii: 10.1007/s10549-020-06022.
    PubMed     Abstract available


  486. PING J, Huang S, Wu J, Bao P, et al
    Association between lincRNA expression and overall survival for patients with triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 Nov 27. pii: 10.1007/s10549-020-06021.
    PubMed     Abstract available


  487. SHAH C, Zambelli-Weiner A, Delgado N, Sier A, et al
    The impact of monitoring techniques on progression to chronic breast cancer-related lymphedema: a meta-analysis comparing bioimpedance spectroscopy versus circumferential measurements.
    Breast Cancer Res Treat. 2020 Nov 27. pii: 10.1007/s10549-020-05988.
    PubMed     Abstract available


  488. PAK LM, Gaither R, Rosenberg SM, Ruddy KJ, et al
    Tumor phenotype and concordance in synchronous bilateral breast cancer in young women.
    Breast Cancer Res Treat. 2020 Nov 26. pii: 10.1007/s10549-020-06027.
    PubMed     Abstract available


  489. BRAAL CL, Hussaarts KGAM, Seuren L, Oomen-deHoop E, et al
    Correction to: Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen.
    Breast Cancer Res Treat. 2020 Nov 23. pii: 10.1007/s10549-020-05979.
    PubMed     Abstract available


  490. RICHMAN J, Ring A, Dowsett M, Sestak I, et al
    Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2020 Nov 21. pii: 10.1007/s10549-020-06013.
    PubMed     Abstract available


  491. CLIFTON K, Luo J, Tao Y, Saam J, et al
    Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA).
    Breast Cancer Res Treat. 2020 Nov 20. pii: 10.1007/s10549-020-06019.
    PubMed     Abstract available


  492. PRAKASH I, Thomas SM, Greenup RA, Plichta JK, et al
    Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer.
    Breast Cancer Res Treat. 2020 Nov 18. pii: 10.1007/s10549-020-06012.
    PubMed     Abstract available


  493. SACHDEV JC, Munster P, Northfelt DW, Han HS, et al
    Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.
    Breast Cancer Res Treat. 2020 Nov 17. pii: 10.1007/s10549-020-05995.
    PubMed     Abstract available


  494. XIE E, Lapinski MM, Talamantes S, Nonyane BAS, et al
    Relationship of circulating immune cells with lifestyle factors and cancer recurrence in early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Nov 13. pii: 10.1007/s10549-020-06016.
    PubMed     Abstract available


  495. CHOBRUTSKIY A, Chobrutskiy BI, Zaman S, Hsiang M, et al
    Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer.
    Breast Cancer Res Treat. 2020 Nov 12. pii: 10.1007/s10549-020-05996.
    PubMed     Abstract available


  496. TROPEE R, de la Pena Avalos B, Gough M, Snell C, et al
    The SWI/SNF subunit SMARCD3 regulates cell cycle progression and predicts survival outcome in ER+ breast cancer.
    Breast Cancer Res Treat. 2020 Nov 12. pii: 10.1007/s10549-020-05997.
    PubMed     Abstract available


  497. LUGTENBERG RT, de Groot S, Kaptein AA, Fischer MJ, et al
    Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013-14) trial.
    Breast Cancer Res Treat. 2020 Nov 11. pii: 10.1007/s10549-020-05991.
    PubMed     Abstract available


  498. SAKHUJA S, Deveaux A, Wilson LE, Vin-Raviv N, et al
    Patterns of de-novo metastasis and breast cancer-specific mortality by race and molecular subtype in the SEER population-based dataset.
    Breast Cancer Res Treat. 2020 Nov 11. pii: 10.1007/s10549-020-06007.
    PubMed     Abstract available


  499. METCALFE KA, Candib A, Giannakeas V, Eisen A, et al
    The relationship between the predicted risk of death and psychosocial functioning among women with early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Nov 10. pii: 10.1007/s10549-020-05992.
    PubMed     Abstract available


  500. PALLESCHI M, Iaia ML, Casadei C
    Germline BRCA-mutated metastatic breast cancer with positive hormone receptor.
    Breast Cancer Res Treat. 2020 Nov 10. pii: 10.1007/s10549-020-06010.
    PubMed    


  501. DAMIN AP, Zancan M, Melo MP, Biazus JV, et al
    Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
    Breast Cancer Res Treat. 2020 Nov 9. pii: 10.1007/s10549-020-06011.
    PubMed     Abstract available


  502. LIU S, Zeng S, Xia L, Yu M, et al
    Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with neoadjuvant therapy.
    Breast Cancer Res Treat. 2020 Nov 9. pii: 10.1007/s10549-020-06015.
    PubMed     Abstract available


  503. ELSHARAWY KA, Althobiti M, Mohammed OJ, Aljohani AI, et al
    Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer.
    Breast Cancer Res Treat. 2020 Nov 8. pii: 10.1007/s10549-020-05999.
    PubMed     Abstract available


  504. SHAH H, Surujballi J, Awan AA, Hutton B, et al
    A scoping review characterizing "Choosing Wisely(R)" recommendations for breast cancer management.
    Breast Cancer Res Treat. 2020 Nov 6. pii: 10.1007/s10549-020-06009.
    PubMed     Abstract available


  505. DAHLMAN D, Magnusson H, Li X, Sundquist J, et al
    Drug use disorder and risk of incident and fatal breast cancer: a nationwide epidemiological study.
    Breast Cancer Res Treat. 2020 Nov 6. pii: 10.1007/s10549-020-05998.
    PubMed     Abstract available


  506. KOPPELMANS V, van der Willik KD, Aleman BMP, van Leeuwen FE, et al
    Long-term effects of adjuvant treatment for breast cancer on carotid plaques and brain perfusion.
    Breast Cancer Res Treat. 2020 Nov 5. pii: 10.1007/s10549-020-05990.
    PubMed     Abstract available


  507. SELLA T, Gelber SI, Poorvu PD, Kim HJ, et al
    Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer.
    Breast Cancer Res Treat. 2020 Nov 4. pii: 10.1007/s10549-020-05989.
    PubMed     Abstract available


  508. CADILI L, DeGirolamo K, McKevitt E, Brown CJ, et al
    COVID-19 and breast cancer at a Regional Breast Centre: our flexible approach during the pandemic.
    Breast Cancer Res Treat. 2020 Nov 4. pii: 10.1007/s10549-020-06008.
    PubMed     Abstract available


  509. SOPIK V
    International variation in breast cancer incidence and mortality in young women.
    Breast Cancer Res Treat. 2020 Nov 3. pii: 10.1007/s10549-020-06003.
    PubMed     Abstract available


  510. CHEN X, Guo K, Lin J
    Letter to the editor regarding the article "Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer".
    Breast Cancer Res Treat. 2020 Nov 2. pii: 10.1007/s10549-020-05987.
    PubMed    


  511. HU X, Myers KS, Oluyemi ET, Philip M, et al
    Presentation and characteristics of breast cancer in young women under age 40.
    Breast Cancer Res Treat. 2020 Nov 2. pii: 10.1007/s10549-020-06000.
    PubMed     Abstract available


    October 2020
  512. WEN Y, Wu X, Peng H, Li C, et al
    Breast cancer risk in patients with polycystic ovary syndrome: a Mendelian randomization analysis.
    Breast Cancer Res Treat. 2020 Oct 31. pii: 10.1007/s10549-020-05973.
    PubMed     Abstract available


  513. KOYUNCU D, Sharma U, Goka ET, Lippman ME, et al
    Spindle assembly checkpoint gene BUB1B is essential in breast cancer cell survival.
    Breast Cancer Res Treat. 2020 Oct 31. pii: 10.1007/s10549-020-05962.
    PubMed     Abstract available


  514. USISKIN I, Li F, Irwin ML, Cartmel B, et al
    Association of relative dose intensity with BMI and pathologic complete response in patients treated with neoadjuvant chemotherapy for breast cancer.
    Breast Cancer Res Treat. 2020 Oct 30. pii: 10.1007/s10549-020-05994.
    PubMed     Abstract available


  515. FINDLAY-SHIRRAS L, Lima I, Smith G, Clemons M, et al
    Canada follows the US in the rise of bilateral mastectomies for unilateral breast cancer: a 23-year population cohort study.
    Breast Cancer Res Treat. 2020 Oct 30. pii: 10.1007/s10549-020-05965.
    PubMed     Abstract available


  516. SHAIK AN, Kiavash K, Stark K, Boerner JL, et al
    Inflammation markers on benign breast biopsy are associated with risk of invasive breast cancer in African American women.
    Breast Cancer Res Treat. 2020 Oct 28. pii: 10.1007/s10549-020-05983.
    PubMed     Abstract available


  517. LATTIMORE V, Parsons MT, Spurdle AB, Pearson J, et al
    Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients.
    Breast Cancer Res Treat. 2020 Oct 28. pii: 10.1007/s10549-020-05986.
    PubMed     Abstract available


  518. DACKUS GMHE, Jozwiak K, van der Wall E, van Diest PJ, et al
    Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer.
    Breast Cancer Res Treat. 2020 Oct 28. pii: 10.1007/s10549-020-05978.
    PubMed     Abstract available


  519. ZHAO F, Copley B, Niu Q, Liu F, et al
    Racial disparities in survival outcomes among breast cancer patients by molecular subtypes.
    Breast Cancer Res Treat. 2020 Oct 27. pii: 10.1007/s10549-020-05984.
    PubMed     Abstract available


  520. HERBERT SL, Wockel A, Kreienberg R, Kuhn T, et al
    To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?
    Breast Cancer Res Treat. 2020 Oct 26. pii: 10.1007/s10549-020-05974.
    PubMed     Abstract available


  521. BREZDEN-MASLEY C, Fathers KE, Coombes ME, Pourmirza B, et al
    A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer.
    Breast Cancer Res Treat. 2020 Oct 22. pii: 10.1007/s10549-020-05976.
    PubMed     Abstract available


  522. KARIRI YA, Alsaleem M, Joseph C, Alsaeed S, et al
    The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer.
    Breast Cancer Res Treat. 2020 Oct 19. pii: 10.1007/s10549-020-05955.
    PubMed     Abstract available


  523. SIMONS JM, Jacobs JG, Roijers JP, Beek MA, et al
    Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study.
    Breast Cancer Res Treat. 2020 Oct 19. pii: 10.1007/s10549-020-05966.
    PubMed     Abstract available


  524. WEISER R, Haque W, Polychronopoulou E, Hatch SS, et al
    The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis.
    Breast Cancer Res Treat. 2020 Oct 18. pii: 10.1007/s10549-020-05971.
    PubMed     Abstract available


  525. GARCIA-TEJEDOR A, Fernandez-Gonzalez S, Ortega R, Gil-Gil M, et al
    Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?
    Breast Cancer Res Treat. 2020 Oct 17. pii: 10.1007/s10549-020-05970.
    PubMed     Abstract available


  526. SIM EJ, Ko KP, Ahn C, Park SM, et al
    Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer.
    Breast Cancer Res Treat. 2020 Oct 17. pii: 10.1007/s10549-020-05875.
    PubMed     Abstract available


  527. LU YC, Huang DW, Chen PT, Tsai CF, et al
    Association between statin use and second cancer risk in breast cancer patients: a nationwide population-based cohort study.
    Breast Cancer Res Treat. 2020 Oct 16. pii: 10.1007/s10549-020-05969.
    PubMed     Abstract available


  528. BREZDEN-MASLEY C, Fathers KE, Coombes ME, Pourmirza B, et al
    A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 Oct 16. pii: 10.1007/s10549-020-05960.
    PubMed     Abstract available


  529. KUMAR R, Kuligina E, Sokolenko A, Siddiqui Q, et al
    Genetic ablation of pregnancy zone protein promotes breast cancer progression by activating TGF-beta/SMAD signaling.
    Breast Cancer Res Treat. 2020 Oct 15. pii: 10.1007/s10549-020-05958.
    PubMed     Abstract available


  530. ZHOU M, Venkata PP, Viswanadhapalli S, Palacios B, et al
    KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
    Breast Cancer Res Treat. 2020 Oct 14. pii: 10.1007/s10549-020-05963.
    PubMed     Abstract available


  531. WU ZY, Kim N, Ko B
    Tumor localization for breast cancer patients receiving neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2020 Oct 14. pii: 10.1007/s10549-020-05950.
    PubMed    


  532. TURNBULL AK, Patel S, Martinez-Perez C, Rigg A, et al
    Risk of chemotherapy-related amenorrhoea (CRA) in premenopausal women undergoing chemotherapy for early stage breast cancer.
    Breast Cancer Res Treat. 2020 Oct 12. pii: 10.1007/s10549-020-05951.
    PubMed     Abstract available


  533. BEN-ZION BERLINER M, Yerushalmi R, Lavie I, Benouaich-Amiel A, et al
    Central nervous system metastases in breast cancer: the impact of age on patterns of development and outcome.
    Breast Cancer Res Treat. 2020 Oct 10. pii: 10.1007/s10549-020-05959.
    PubMed     Abstract available


  534. HATONO M, Ikeda H, Suzuki Y, Kajiwara Y, et al
    Effect of isoflavones on breast cancer cell development and their impact on breast cancer treatments.
    Breast Cancer Res Treat. 2020 Oct 9. pii: 10.1007/s10549-020-05957.
    PubMed     Abstract available


  535. PESCE C, Jaffe J, Kuchta K, Yao K, et al
    Patient-reported outcomes among women with unilateral breast cancer undergoing breast conservation versus single or double mastectomy.
    Breast Cancer Res Treat. 2020 Oct 8. pii: 10.1007/s10549-020-05964.
    PubMed     Abstract available


  536. ABRAHAM HG, Xia Y, Mukherjee B, Merajver SD, et al
    Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database.
    Breast Cancer Res Treat. 2020 Oct 8. pii: 10.1007/s10549-020-05938.
    PubMed     Abstract available


  537. FILHO OM, Giobbie-Hurder A, Lin NU, Faggen M, et al
    A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 Oct 6. pii: 10.1007/s10549-020-05928.
    PubMed     Abstract available


  538. GOYAL A, Puri S, Marshall A, Valassiadou K, et al
    A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients.
    Breast Cancer Res Treat. 2020 Oct 6. pii: 10.1007/s10549-020-05961.
    PubMed     Abstract available


  539. PARK JW, Han K, Shin DW, Yeo Y, et al
    Obesity and breast cancer risk for pre- and postmenopausal women among over 6 million Korean women.
    Breast Cancer Res Treat. 2020 Oct 3. pii: 10.1007/s10549-020-05952.
    PubMed     Abstract available


  540. KOELMEYER LA, Moloney E, Boyages J, Sherman KA, et al
    Prospective surveillance model in the home for breast cancer-related lymphoedema: a feasibility study.
    Breast Cancer Res Treat. 2020 Oct 1. pii: 10.1007/s10549-020-05953.
    PubMed     Abstract available


  541. YAN S, Dey P, Ziegler Y, Jiao X, et al
    Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer.
    Breast Cancer Res Treat. 2020 Oct 1. pii: 10.1007/s10549-020-05948.
    PubMed     Abstract available


  542. LAI V, Hajjaj O, Le D, Shokoohi A, et al
    Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes? : Time from Neoadjuvant Chemotherapy to Surgery.
    Breast Cancer Res Treat. 2020 Oct 1. pii: 10.1007/s10549-020-05894.
    PubMed     Abstract available


    September 2020
  543. VAN RAEMDONCK E, Floris G, Berteloot P, Laenen A, et al
    Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Sep 27. pii: 10.1007/s10549-020-05935.
    PubMed     Abstract available


  544. JIANG YZ, Ge LP, Jin X, Fan L, et al
    Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations.
    Breast Cancer Res Treat. 2020 Sep 25. pii: 10.1007/s10549-020-05940.
    PubMed     Abstract available


  545. HERNANZ F
    Comments on patient-reported outcome after oncoplastic breast surgery compared with conventional breast-conserving surgery in breast cancer.
    Breast Cancer Res Treat. 2020 Sep 24. pii: 10.1007/s10549-020-05945.
    PubMed    


  546. MOHAMADZADE Z, Mahjoubi F, Soltani BM
    Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer.
    Breast Cancer Res Treat. 2020 Sep 24. pii: 10.1007/s10549-020-05937.
    PubMed     Abstract available


  547. ZAHL PH, Kristiansen IS
    Re: Stage-specific survival has improved for young breast cancer patients since 2000: but not equally?
    Breast Cancer Res Treat. 2020 Sep 24. pii: 10.1007/s10549-020-05941.
    PubMed    


  548. ABDEL-RAZEQ H, Edaily S, Iweir S, Salam M, et al
    Effect of level of hormone-receptor expression on treatment outcomes of "triple-positive" early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Sep 24. pii: 10.1007/s10549-020-05942.
    PubMed     Abstract available


  549. MARSH S, Borges VF, Coons HL, Afghahi A, et al
    Sexual health after a breast cancer diagnosis in young women: clinical implications for patients and providers.
    Breast Cancer Res Treat. 2020 Sep 23. pii: 10.1007/s10549-020-05880.
    PubMed     Abstract available


  550. JACOBSE JN, Schaapveld M, Boekel NB, Hooning MJ, et al
    Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study.
    Breast Cancer Res Treat. 2020 Sep 22. pii: 10.1007/s10549-020-05930.
    PubMed     Abstract available


  551. NICHOLS HB, Graff M, Bensen JT, Lunetta KL, et al
    Genetic variants in anti-Mullerian hormone-related genes and breast cancer risk: results from the AMBER consortium.
    Breast Cancer Res Treat. 2020 Sep 22. pii: 10.1007/s10549-020-05944.
    PubMed     Abstract available


  552. JERZAK KJ, Lohmann AE, Ennis M, Nemeth E, et al
    Prognostic associations of plasma hepcidin in women with early breast cancer.
    Breast Cancer Res Treat. 2020 Sep 22. pii: 10.1007/s10549-020-05903.
    PubMed     Abstract available


  553. KONISHI T, Fujiogi M, Michihata N, Morita K, et al
    Association between body mass index and localization of breast cancer: results from a nationwide inpatient database in Japan.
    Breast Cancer Res Treat. 2020 Sep 19. pii: 10.1007/s10549-020-05934.
    PubMed     Abstract available


  554. TIAINEN S, Rilla K, Hamalainen K, Oikari S, et al
    The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype.
    Breast Cancer Res Treat. 2020 Sep 18. pii: 10.1007/s10549-020-05925.
    PubMed     Abstract available


  555. GEBREMARIAM A, Dereje N, Addissie A, Worku A, et al
    Factors associated with late-stage diagnosis of breast cancer among women in Addis Ababa, Ethiopia.
    Breast Cancer Res Treat. 2020 Sep 18. pii: 10.1007/s10549-020-05919.
    PubMed     Abstract available


  556. GUVAKOVA MA, Prabakaran I, Wu Z, Hoffman DI, et al
    CDH2/N-cadherin and early diagnosis of invasion in patients with ductal carcinoma in situ.
    Breast Cancer Res Treat. 2020;183:333-346.
    PubMed     Abstract available


  557. BROWNE JL, Korsun N, Casas L, Rodriguez I, et al
    "Are changes in breast density during the menstrual cycle relevant? To what?"
    Breast Cancer Res Treat. 2020;183:451-458.
    PubMed     Abstract available


  558. KAIDAR-PERSON O, Poortmans P, Offersen BV, Siesling S, et al
    Spatial location of local recurrences after mastectomy: a systematic review.
    Breast Cancer Res Treat. 2020;183:263-273.
    PubMed     Abstract available


  559. WONG EC, Kaplan CP, Barulich M, Melisko M, et al
    Assessing preferences for receiving supportive care resources among patients seen at a Breast Care Center.
    Breast Cancer Res Treat. 2020;183:381-389.
    PubMed     Abstract available


  560. JUNG JJ, Kang E, Kim EK, Kim SM, et al
    External validation and modification of nomogram for predicting positive resection margins before breast conserving surgery.
    Breast Cancer Res Treat. 2020;183:373-380.
    PubMed     Abstract available


  561. LI K, Liao N, Chen B, Zhang G, et al
    Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
    Breast Cancer Res Treat. 2020;183:321-332.
    PubMed     Abstract available


  562. HENDRIKS MP, Verbeek XAAM, van Manen JG, van der Heijden SE, et al
    Clinical decision trees support systematic evaluation of multidisciplinary team recommendations.
    Breast Cancer Res Treat. 2020;183:355-363.
    PubMed     Abstract available


  563. GOEL AK, Zamre V, Hari S
    Variation in pathological complete response in HER2-positive breast cancers with intrinsic subtypes assessed by PAM50 testing: secondary analysis from NSABP B-41 trial.
    Breast Cancer Res Treat. 2020;183:489-490.
    PubMed    


    August 2020
  564. KOPPARTHY P, Daily K
    A case for Tamoxifen with ovarian function suppression.
    Breast Cancer Res Treat. 2020;183:241-242.
    PubMed    


  565. AZAM S, Jacobsen KK, Aro AR, Lynge E, et al
    Hormone replacement therapy and mammographic density: a systematic literature review.
    Breast Cancer Res Treat. 2020;182:555-579.
    PubMed     Abstract available


  566. ABBATE O, Rosado N, Sobti N, Vieira BL, et al
    Meta-analysis of prepectoral implant-based breast reconstruction: guide to patient selection and current outcomes.
    Breast Cancer Res Treat. 2020;182:543-554.
    PubMed     Abstract available


  567. LEEVAN E, Ho BT, Seto S, Shen J, et al
    Use of MarginProbe as an adjunct to standard operating procedure does not significantly reduce re-excision rates in breast conserving surgery.
    Breast Cancer Res Treat. 2020;183:145-151.
    PubMed     Abstract available


  568. NAOUM GE, Oladeru OT, Niemierko A, Salama L, et al
    Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy.
    Breast Cancer Res Treat. 2020;183:127-136.
    PubMed     Abstract available


  569. LIU D
    Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
    Breast Cancer Res Treat. 2020;183:95-105.
    PubMed     Abstract available


    July 2020
  570. VAN STEENHOVEN JEC, den Dekker BM, Kuijer A, van Diest PJ, et al
    Patients' perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict.
    Breast Cancer Res Treat. 2020;182:107-115.
    PubMed     Abstract available


  571. RAMZI S, Najeeb E, Coulthard J, Jenkins S, et al
    Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good?
    Breast Cancer Res Treat. 2020;182:47-54.
    PubMed     Abstract available


  572. DOFARA SG, Chang SL, Diorio C
    Association between the polymorphisms in MMP-2 and MMP-9 with adiposity and mammographic features.
    Breast Cancer Res Treat. 2020;182:169-179.
    PubMed     Abstract available


  573. PASZAT L, Sutradhar R, Rakovitch E
    The impact of ductal carcinoma in situ on health services utilization.
    Breast Cancer Res Treat. 2020;182:159-168.
    PubMed     Abstract available


  574. WATANABE T, Honda T, Totsuka H, Yoshida M, et al
    Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
    Breast Cancer Res Treat. 2020;182:491-502.
    PubMed     Abstract available


  575. MISRA S, Lee G, Maganti M, Koch CA, et al
    Utilization patterns and temporal trends of internal mammary nodal irradiation at a tertiary cancer center.
    Breast Cancer Res Treat. 2020;182:367-379.
    PubMed     Abstract available


  576. PALVE JS, Luukkaala TH, Kaariainen MT
    Predictive risk factors of complications in different breast reconstruction methods.
    Breast Cancer Res Treat. 2020;182:345-354.
    PubMed     Abstract available


  577. IWAMOTO T, Hara F, Uemura Y, Mukai H, et al
    NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy.
    Breast Cancer Res Treat. 2020;182:325-332.
    PubMed     Abstract available


  578. HASSAN Z, Boulos F, Abbas J, El Charif MH, et al
    Intracystic papillary carcinoma: clinical presentation, patterns of practice, and oncological outcomes.
    Breast Cancer Res Treat. 2020;182:317-323.
    PubMed     Abstract available


  579. LEE MK, Sanaiha Y, Kusske AM, Thompson CK, et al
    A comparison of two non-radioactive alternatives to wire for the localization of non-palpable breast cancers.
    Breast Cancer Res Treat. 2020;182:299-303.
    PubMed     Abstract available


  580. ANGARITA FA, Acuna SA, Cordeiro E, McCready DR, et al
    Does oncoplastic surgery increase immediate (30-day) postoperative complications? An analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database.
    Breast Cancer Res Treat. 2020;182:429-438.
    PubMed     Abstract available


  581. CRAGUN D, Weidner A, Tezak A, Clouse K, et al
    Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Breast Cancer Res Treat. 2020;182:421-428.
    PubMed     Abstract available


    June 2020
  582. BERNSTEIN-MOLHO R, Friedman E, Kedar I, Laitman Y, et al
    Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants.
    Breast Cancer Res Treat. 2020;181:445-453.
    PubMed     Abstract available


  583. NOORDMAN PCW, Klioueva NM, Weimann MN, Borgstein PJ, et al
    Phyllodes tumors of the breast: a retrospective analysis of 57 cases.
    Breast Cancer Res Treat. 2020;181:361-367.
    PubMed     Abstract available


  584. DOLEN U, Thornton M, Tenenbaum MM, Aripoli A, et al
    A prospective cohort study to analyze the interaction of tumor-to-breast volume in breast conservation therapy versus mastectomy with reconstruction.
    Breast Cancer Res Treat. 2020;181:611-621.
    PubMed     Abstract available


  585. BIJKERK E, van Kuijk SMJ, Lataster A, van der Hulst RRWJ, et al
    Breast sensibility in bilateral autologous breast reconstruction with unilateral sensory nerve coaptation.
    Breast Cancer Res Treat. 2020;181:599-610.
    PubMed     Abstract available


  586. JIA M, Lin X, Zhou X, Yan H, et al
    Diagnostic performance of automated breast ultrasound and handheld ultrasound in women with dense breasts.
    Breast Cancer Res Treat. 2020;181:589-597.
    PubMed     Abstract available


  587. SHEN T, Nitta H, Wei L, Parwani AV, et al
    HER2 intratumoral heterogeneity is independently associated with distal metastasis and overall survival in HER2-positive breast carcinomas.
    Breast Cancer Res Treat. 2020;181:519-527.
    PubMed     Abstract available


  588. OBDEIJN IM, Mann RM, Loo CCE, Lobbes M, et al
    The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2020;181:581-588.
    PubMed     Abstract available


    May 2020
  589. MUKHTAR RA, Krings G, Chen YY, Mamounas ME, et al
    Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
    Breast Cancer Res Treat. 2020;181:23-29.
    PubMed     Abstract available


  590. DO WL, Conneely K, Gabram-Mendola S, Krishnamurti U, et al
    Obesity-associated methylation in breast tumors: a possible link to disparate outcomes?
    Breast Cancer Res Treat. 2020;181:135-144.
    PubMed     Abstract available


  591. PURRINGTON KS, Gorski D, Simon MS, Hastert TA, et al
    Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers.
    Breast Cancer Res Treat. 2020;181:145-154.
    PubMed     Abstract available


  592. OLIVERI S, Ongaro G, Durosini I, Curigliano G, et al
    Breast implant-associated anaplastic large cell lymphoma: emotional impact and guidelines for psychological support.
    Breast Cancer Res Treat. 2020;181:221-224.
    PubMed     Abstract available


  593. LIU W, Li W, Li Z, Shi L, et al
    Ultrasound characteristics of sclerosing adenosis mimicking breast carcinoma.
    Breast Cancer Res Treat. 2020;181:127-134.
    PubMed     Abstract available


  594. FRASSON AL, Lichtenfels M, de Souza AAB, Vollbrecht B, et al
    Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.
    Breast Cancer Res Treat. 2020;181:69-75.
    PubMed     Abstract available


    April 2020
  595. SUNAGUCHI N, Shimao D, Yuasa T, Ichihara S, et al
    Three-dimensional microanatomy of human nipple visualized by X-ray dark-field computed tomography.
    Breast Cancer Res Treat. 2020;180:397-405.
    PubMed     Abstract available


  596. KATZ MS, McCall L, Ballman K, Jagsi R, et al
    Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations.
    Breast Cancer Res Treat. 2020;180:429-436.
    PubMed     Abstract available


  597. SEOW DYB, Yeong JPS, Lim JX, Chia N, et al
    Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers.
    Breast Cancer Res Treat. 2020;180:369-377.
    PubMed     Abstract available


  598. STUMPF CC, Zucatto AE, Cavalheiro JAC, de Melo MP, et al
    Oncologic safety of immediate autologous fat grafting for reconstruction in breast-conserving surgery.
    Breast Cancer Res Treat. 2020;180:301-309.
    PubMed     Abstract available


  599. LI AC, Zhao J, Zhao C, Ma Z, et al
    Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
    Breast Cancer Res Treat. 2020;180:321-329.
    PubMed     Abstract available


  600. JENNARO TS, Fang F, Kidwell KM, Smith EML, et al
    Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy.
    Breast Cancer Res Treat. 2020;180:707-714.
    PubMed     Abstract available


  601. YARDLEY DA, Peacock N, Daniel B, Anz B, et al
    Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2020;180:647-655.
    PubMed     Abstract available


    February 2020
  602. MEIER DR, Girtman MA, Lofgren KA, Kenny PA, et al
    Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice.
    Breast Cancer Res Treat. 2020;179:653-660.
    PubMed     Abstract available


  603. KYKER-SNOWMAN K, Hughes RM, Yankaskas CL, Cravero K, et al
    TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties.
    Breast Cancer Res Treat. 2020;179:631-642.
    PubMed     Abstract available


  604. BROWNE JL, Casas L, Santandreu G, Rodriguez I, et al
    Breast density measured volumetrically in a clinical environment: cross-sectional study with photon counting technology.
    Breast Cancer Res Treat. 2020;179:755-762.
    PubMed     Abstract available


  605. LOOK HONG N, Wright FC, Semple M, Nicolae AM, et al
    Results of a phase I, non-randomized study evaluating a Magnetic Occult Lesion Localization Instrument (MOLLI) for excision of non-palpable breast lesions.
    Breast Cancer Res Treat. 2020;179:671-676.
    PubMed     Abstract available


  606. PIROT F, Chaltiel D, Ben Lakhdar A, Mathieu MC, et al
    Squamous cell carcinoma of the breast, are there two entities with distinct prognosis? A series of 39 patients.
    Breast Cancer Res Treat. 2020;180:87-95.
    PubMed     Abstract available


  607. ADHIKARY S, Hoskin TL, Stallings-Mann ML, Arshad M, et al
    Cytotoxic T cell depletion with increasing epithelial abnormality in women with benign breast disease.
    Breast Cancer Res Treat. 2020;180:55-61.
    PubMed     Abstract available


    January 2020
  608. MITRA D, Bhattacharyya S, Alam N, Sen S, et al
    Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast.
    Breast Cancer Res Treat. 2020;179:359-370.
    PubMed     Abstract available


  609. MERRILL NM, Lachacz EJ, Vandecan NM, Ulintz PJ, et al
    Molecular determinants of drug response in TNBC cell lines.
    Breast Cancer Res Treat. 2020;179:337-347.
    PubMed     Abstract available


  610. FUNK A, Heil J, Harcos A, Gomez C, et al
    Efficacy of intraoperative specimen radiography as margin assessment tool in breast conserving surgery.
    Breast Cancer Res Treat. 2020;179:425-433.
    PubMed     Abstract available


  611. MULLOOLY M, Withrow DR, Curtis RE, Fan S, et al
    Association of lifestyle and clinical characteristics with receipt of radiotherapy treatment among women diagnosed with DCIS in the NIH-AARP Diet and Health Study.
    Breast Cancer Res Treat. 2020;179:445-457.
    PubMed     Abstract available


  612. BERRY DL, Blonquist TM, Halpenny B, Hong F, et al
    The Jacki Jacket after mastectomy with reconstruction: a randomized pilot study.
    Breast Cancer Res Treat. 2020;179:377-385.
    PubMed     Abstract available


  613. NEALON KP, Sobti N, Gadd M, Specht M, et al
    Assessing the additional surgical risk of contralateral prophylactic mastectomy and immediate breast implant reconstruction.
    Breast Cancer Res Treat. 2020;179:255-265.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: